AI in Life Science Market by Offering (End-to-End, Niche/Point, AI Tech), Application (Drug Discovery, Clinical Trials, Quality Assurance, Regulatory), Tool (Machine Learning, NLP, Computer Vision), End User (Pharma, Biotech) - Global Forecast to 2031
The AI in life science market is projected to reach USD 69.34 billion by 2031, up from USD 21.58 billion in 2026, at a high CAGR of 26.3% over the forecast period.
The growth rate is further fueled by the growing trend toward data-oriented and agentic AI architectures that help life science companies advance from conventional analytics to self-acting systems. These innovations particularly impact clinical trial optimization, real-world evidence collection, and post-market monitoring, as fragmented and vast data sets have limited the efficiency of these applications. In addition, the adoption of cloud-based services with AI technology allows life science companies to consolidate diverse data sources, ranging from medical and genomics data to patient-specific information, to facilitate predictive modeling and fast-track the drug development process. The emergence of AI agents that automate sophisticated tasks, such as literature search, hypothesis formulation, and patient segmentation, also contributes to increased operational efficiency and accelerated innovation cycles. For example, Oracle Corporation (US) released the Oracle Life Sciences AI Data Platform in January 2026, which combines more than 129 million de-identified medical records with generative AI and agentic intelligence solutions to speed up research and clinical trials. In addition, IQVIA Holdings Inc. (US) introduced AI agents in June 2025 to optimize workflows in clinical and commercial operations, including target identification and clinical data analytics.
Based on region, the AI in life science market is segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. North America is the dominant region in the global AI in life science market owing to the presence of sophisticated research networks, high levels of digitalization, and considerable investment in innovations in biotechnology and pharma. The region leverages its strengths in terms of synergies between universities, hospitals, and tech companies, helping to implement AI-driven advancements more quickly. Moreover, a positive regulatory environment and rapid adoption of sophisticated analytics in drug discovery and clinical trials have helped to consolidate the region's position as a leader in this market. Europe is the second-largest market in the segment due to the growing interest of governments and companies in Al technology and AI products compliant with data privacy requirements.
Based on offerings, the AI in life science market is divided into end-to-end solutions, niche/point solutions, AI technology, and services. In 2025, end-to-end solutions had the largest market share due to increasing demand for integrated platforms that support data ingestion, model building, validation, and deployment across the entire life sciences value chain. These solutions make the life sciences workflow more efficient and cohesive, from target identification to clinical and commercial levels. Companies in the industry now tend to prefer full-stack AI platforms over stand-alone software for their ability to scale, comply with regulations, and enable collaboration across functions. This shift reflects a broader market trend moving from experimental AI applications toward enterprise-level implementation that requires consistent, repeatable, and auditable processes for research and development and clinical trials. For example, in October 2025, the Italian organization expert.ai launched AI-powered solutions to optimize clinical trial design and regulatory and research workflows. Additionally, in June 2025, ArisGlobal (US) implemented its LifeSphere NavaX AI platform at a leading pharmaceutical company globally, enabling automated analysis of roughly 350,000 safety cases annually.
Based on application, the AI in life science market is divided into clinical applications and non-clinical applications. The clinical applications segment is expected to see the fastest growth in this market. This is attributed to the rise in the use of AI to improve patient experiences, conduct clinical trials more effectively, and adopt precision medicine through real-time data analysis. AI-powered software is helping to improve patient enrollment, trial management, and protocol optimization, thereby reducing trial periods and improving success rates. In addition, the transition toward patient-focused, decentralized clinical trials is driving the adoption of AI-powered software. This trend was reflected in the following development. By March 2026, IQVIA had deployed over 150 AI agents, which were used by 19 of the top 20 pharmaceutical firms. In June 2025, IQVIA Holdings Inc. (US) released AI agents to streamline clinical operations.
The growth rate is further fueled by the growing trend toward data-oriented and agentic AI architectures that help life science companies advance from conventional analytics to self-acting systems. These innovations particularly impact clinical trial optimization, real-world evidence collection, and post-market monitoring, as fragmented and vast data sets have limited the efficiency of these applications. In addition, the adoption of cloud-based services with AI technology allows life science companies to consolidate diverse data sources, ranging from medical and genomics data to patient-specific information, to facilitate predictive modeling and fast-track the drug development process. The emergence of AI agents that automate sophisticated tasks, such as literature search, hypothesis formulation, and patient segmentation, also contributes to increased operational efficiency and accelerated innovation cycles. For example, Oracle Corporation (US) released the Oracle Life Sciences AI Data Platform in January 2026, which combines more than 129 million de-identified medical records with generative AI and agentic intelligence solutions to speed up research and clinical trials. In addition, IQVIA Holdings Inc. (US) introduced AI agents in June 2025 to optimize workflows in clinical and commercial operations, including target identification and clinical data analytics.
Based on region, the AI in life science market is segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. North America is the dominant region in the global AI in life science market owing to the presence of sophisticated research networks, high levels of digitalization, and considerable investment in innovations in biotechnology and pharma. The region leverages its strengths in terms of synergies between universities, hospitals, and tech companies, helping to implement AI-driven advancements more quickly. Moreover, a positive regulatory environment and rapid adoption of sophisticated analytics in drug discovery and clinical trials have helped to consolidate the region's position as a leader in this market. Europe is the second-largest market in the segment due to the growing interest of governments and companies in Al technology and AI products compliant with data privacy requirements.
Based on offerings, the AI in life science market is divided into end-to-end solutions, niche/point solutions, AI technology, and services. In 2025, end-to-end solutions had the largest market share due to increasing demand for integrated platforms that support data ingestion, model building, validation, and deployment across the entire life sciences value chain. These solutions make the life sciences workflow more efficient and cohesive, from target identification to clinical and commercial levels. Companies in the industry now tend to prefer full-stack AI platforms over stand-alone software for their ability to scale, comply with regulations, and enable collaboration across functions. This shift reflects a broader market trend moving from experimental AI applications toward enterprise-level implementation that requires consistent, repeatable, and auditable processes for research and development and clinical trials. For example, in October 2025, the Italian organization expert.ai launched AI-powered solutions to optimize clinical trial design and regulatory and research workflows. Additionally, in June 2025, ArisGlobal (US) implemented its LifeSphere NavaX AI platform at a leading pharmaceutical company globally, enabling automated analysis of roughly 350,000 safety cases annually.
Based on application, the AI in life science market is divided into clinical applications and non-clinical applications. The clinical applications segment is expected to see the fastest growth in this market. This is attributed to the rise in the use of AI to improve patient experiences, conduct clinical trials more effectively, and adopt precision medicine through real-time data analysis. AI-powered software is helping to improve patient enrollment, trial management, and protocol optimization, thereby reducing trial periods and improving success rates. In addition, the transition toward patient-focused, decentralized clinical trials is driving the adoption of AI-powered software. This trend was reflected in the following development. By March 2026, IQVIA had deployed over 150 AI agents, which were used by 19 of the top 20 pharmaceutical firms. In June 2025, IQVIA Holdings Inc. (US) released AI agents to streamline clinical operations.
1 INTRODUCTION
1.1 STUDY OBJECTIVES
1.2 MARKET DEFINITION
1.3 STUDY SCOPE
1.3.1 MARKET SEGMENTATION AND REGIONAL SCOPE
1.3.2 INCLUSIONS AND EXCLUSIONS
1.3.3 YEARS CONSIDERED
1.4 CURRENCY CONSIDERED
1.5 STAKEHOLDERS
2 EXECUTIVE SUMMARY
2.1 KEY INSIGHTS AND MARKET HIGHLIGHTS
2.2 KEY MARKET PARTICIPANTS: SHARE INSIGHTS AND STRATEGIC DEVELOPMENTS
2.3 DISRUPTIVE TRENDS SHAPING THE MARKET
2.4 HIGH-GROWTH SEGMENTS & EMERGING FRONTIERS
2.5 SNAPSHOT: GLOBAL MARKET SIZE, GROWTH RATE, AND FORECAST
3 PREMIUM INSIGHTS
3.1 AI IN LIFE SCIENCE MARKET OVERVIEW
3.2 AI IN LIFE SCIENCE MARKET, BY APPLICATION & REGION
3.3 AI IN LIFE SCIENCE MARKET: REGIONAL SNAPSHOT
4 MARKET OVERVIEW
4.1 INTRODUCTION
4.2 MARKET DYNAMICS
4.2.1 DRIVERS
4.2.1.1 Surging demand for accelerated drug discovery and R&D pipeline optimization
4.2.1.2 Growing cross-industry partnerships
4.2.1.3 Expanding applications of AI in clinical trial design, patient recruitment, and operational efficiency
4.2.1.4 Growing availability of large-scale biomedical datasets and advances in computing infrastructure
4.2.1.5 Supportive government policies, funding initiatives, and regulatory frameworks
4.2.2 RESTRAINTS
4.2.2.1 Data privacy and cybersecurity concerns
4.2.2.2 Algorithmic bias and clinician trust deficits
4.2.2.3 High implementation costs, technical complexity, and integration challenges with legacy IT systems
4.2.3 OPPORTUNITIES
4.2.3.1 Generative AI and foundation models for de novo drug design
4.2.3.2 Rising focus on rare disease treatments
4.2.3.3 Growing demand for precision and personalized medicine
4.2.3.4 AI integration in academic research institutes and government-backed biomedical innovation programs
4.2.4 CHALLENGES
4.2.4.1 Low data fragmentation, interoperability deficits
4.2.4.2 Talent scarcity and organizational readiness
4.3 UNMET NEEDS AND WHITE SPACES
4.4 INTERCONNECTED MARKETS AND CROSS-SECTOR OPPORTUNITIES
4.5 STRATEGIC MOVES BY TIER-1/2/3 PLAYERS
5 INDUSTRY TRENDS
5.1 PORTER’S FIVE FORCES ANALYSIS
5.1.1 BARGAINING POWER OF SUPPLIERS
5.1.2 BARGAINING POWER OF BUYERS
5.1.3 THREAT OF SUBSTITUTES
5.1.4 THREAT OF NEW ENTRANTS
5.1.5 INTENSITY OF COMPETITIVE RIVALRY
5.2 MACROECONOMIC INDICATORS
5.2.1 INTRODUCTION
5.2.2 GDP TRENDS AND FORECAST
5.2.3 TRENDS IN GLOBAL HEALTHCARE IT INDUSTRY
5.3 VALUE CHAIN ANALYSIS
5.4 ECOSYSTEM ANALYSIS
5.5 PRICING ANALYSIS
5.5.1 INDICATIVE PRICE FOR AI IN LIFE SCIENCE MARKET (2025)
5.5.2 INDICATIVE PRICE FOR AI IN LIFE SCIENCE MARKET, BY REGION (2025)
5.6 KEY CONFERENCES AND EVENTS, 2026–2027
5.7 TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS
5.8 INVESTMENT AND FUNDING SCENARIO
5.9 CASE STUDY ANALYSIS
5.10 IMPACT OF 2025 US TARIFF – AI IN LIFE SCIENCE MARKET
5.10.1 INTRODUCTION
5.10.2 KEY TARIFF RATES
5.10.3 PRICE IMPACT ANALYSIS
5.10.4 IMPACT ON COUNTRY/REGION
5.10.4.1 US
5.10.4.2 Europe
5.10.4.3 Asia Pacific
5.10.5 IMPACT ON END USERS
5.10.5.1 CRO & CDMO
5.10.5.2 Pharmaceutical & biotechnology companies
5.10.5.3 Research centers & academic institutes
5.10.5.4 Diagnostic companies
6 REGULATORY LANDSCAPE
6.1 REGIONAL REGULATIONS AND COMPLIANCE
6.1.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
6.1.2 NORTH AMERICA
6.1.3 EUROPE
6.1.4 ASIA PACIFIC
6.1.5 MIDDLE EAST & AFRICA
6.1.6 LATIN AMERICA
6.1.7 INDUSTRY STANDARDS
7 STRATEGIC DISRUPTION THROUGH TECHNOLOGY, PATENTS, DIGITAL, AND AI ADOPTION
7.1 KEY EMERGING TECHNOLOGIES
7.1.1 GRAPH NEURAL NETWORKS
7.1.2 COMPUTER VISION
7.1.3 PREDICTIVE ANALYTICS
7.2 COMPLEMENTARY TECHNOLOGIES
7.2.1 NEXT-GENERATION SEQUENCING
7.2.2 REAL-WORLD EVIDENCE/REAL-WORLD DATA
7.2.3 PERSONALIZATION ENGINES
7.3 ADJACENT TECHNOLOGIES
7.3.1 CLOUD COMPUTING
7.3.2 BLOCKCHAIN
7.3.3 BIG DATA & ADVANCED ANALYTICS
7.4 TECHNOLOGY/PRODUCT ROADMAP
7.5 PATENT ANALYSIS
7.5.1 INSIGHTS: JURISDICTION AND TOP APPLICANT ANALYSIS
7.6 FUTURE APPLICATIONS
7.6.1 AI-DRIVEN DRUG DISCOVERY
7.6.2 GENOMIC ANALYSIS
7.6.3 PRECISION MEDICINE
7.6.4 VIRTUAL DRUG SCREENING
8 CUSTOMER LANDSCAPE & BUYER BEHAVIOR
8.1 INTRODUCTION
8.2 DECISION-MAKING PROCESS
8.3 BUYER STAKEHOLDERS AND BUYING EVALUATION CRITERIA
8.3.1 KEY STAKEHOLDERS IN BUYING PROCESS
8.3.2 BUYING CRITERIA
8.4 ADOPTION BARRIERS & INTERNAL CHALLENGES
8.5 UNMET NEEDS FROM VARIOUS END-USE INDUSTRIES
8.5.1 UNMET NEEDS
8.5.2 END USER EXPECTATIONS
8.6 MARKET PROFITABILITY
9 AI IN LIFE SCIENCE MARKET, BY TOOL
9.1 INTRODUCTION
9.2 MACHINE LEARNING
9.2.1 DEEP LEARNING
9.2.1.1 Convolutional neural networks
9.2.1.1.1 High-sensitivity medical imaging AI across oncology and radiology pathways – key driver
9.2.1.2 Recurrent neural networks
9.2.1.2.1 Sequential biological data processing drives adoption in clinical and genomic applications
9.2.1.3 Generative adversarial networks
9.2.1.3.1 Synthetic data generation to overcome life science data scarcity barriers boosts adoption
9.2.1.4 Graph neural networks
9.2.1.4.1 Graph AI architectures modeling molecular interactions to advance target and pathway discovery
9.2.1.5 Others
9.2.1.5.1 Transformer and diffusion architectures expanding deep learning frontiers in life sciences
9.2.2 SUPERVISED LEARNING
9.2.2.1 Segment driven by accurate prediction of compound potency and selectivity across diverse chemical series
9.2.3 REINFORCEMENT LEARNING
9.2.3.1 Optimized drug dosing, trial design, and autonomous laboratory systems to drive segment
9.2.4 UNSUPERVISED LEARNING
9.2.4.1 Unsupervised AI revealing hidden biological patterns within high-dimensional omics datasets
9.2.5 OTHER MACHINE LEARNING TECHNOLOGIES
9.2.5.1 Semi-supervised and federated learning overcome data scarcity and privacy constraints
9.3 NATURAL LANGUAGE PROCESSING
9.3.1 BIOMEDICAL LLMS AND CLINICAL NLP AUTOMATING KNOWLEDGE EXTRACTION FROM UNSTRUCTURED HEALTH DATA
9.4 CONTEXT-AWARE PROCESSING AND COMPUTING
9.4.1 SEGMENT DRIVEN BY DYNAMIC, PATIENT-SPECIFIC INSIGHTS ACROSS CLINICAL WORKFLOWS
9.5 COMPUTER VISION
9.5.1 TRANSFORMATION OF PATHOLOGY, DERMATOLOGY, AND DRUG MANUFACTURING INSPECTION PROCESSES – KEY DRIVERS
9.6 IMAGE ANALYSIS
9.6.1 ACCELERATED DIGITAL PATHOLOGY, LAB IMAGING, AND DOCUMENT PROCESSING TO BOOST ADOPTION
9.7 OTHER TOOLS
10 AI IN LIFE SCIENCE MARKET, BY APPLICATION
10.1 INTRODUCTION
10.2 CLINICAL APPLICATIONS
10.2.1 REDUCED DEVELOPMENT TIMELINES AND IMPROVED CLINICAL SUCCESS TO DRIVE SEGMENT
10.2.2 DRUG DISCOVERY
10.2.2.1 AI-driven target identification transforming biopharma R&D productivity and success rates
10.2.3 MEDICAL IMAGING & DIAGNOSTICS
10.2.3.1 Accelerating FDA clearances and radiology digitization drives clinical AI imaging adoption
10.2.4 CLINICAL TRIALS
10.2.4.1 AI-powered trial optimization and decentralized models accelerating patient-centric research
10.2.5 PRECISION MEDICINE
10.2.5.1 Multi-Omics AI integration enabling individualized therapy selection at population scale
10.2.6 OTHER CLINICAL APPLICATIONS
10.2.6.1 AI-augmented clinical decision support expanding into pharmacovigilance and rare disease
10.3 NON-CLINICAL APPLICATIONS
10.3.1 R&D SUPPORT
10.3.1.1 AI-enabled literature mining and lab automation multiplying R&D throughput significantly
10.3.2 DATA ANALYTICS & REPORTING
10.3.2.1 Real-world evidence and AI analytics transforming strategic decision-making across organizations
10.3.3 MANUFACTURING & QUALITY ASSURANCE
10.3.3.1 Predictive quality AI and continuous manufacturing reduce batch failures and compliance risk
10.3.4 REGULATORY AFFAIRS
10.3.4.1 FDA and EMA AI guidance catalyzing regulatory submission automation and pharmacovigilance efficiency
11 AI IN LIFE SCIENCE MARKET, BY COMPONENT
11.1 INTRODUCTION
11.2 SOFTWARE
11.2.1 AI SOFTWARE PLATFORMS BECOMING CORE INFRASTRUCTURE FOR LIFE SCIENCE DIGITAL TRANSFORMATION
11.3 SERVICE
11.3.1 SPECIALIZED AI SERVICES BRIDGING VALIDATION AND COMPLIANCE GAPS ACROSS LIFE SCIENCE ENTERPRISES
12 AI IN LIFE SCIENCE MARKET, BY DEPLOYMENT
12.1 INTRODUCTION
12.2 CLOUD-BASED SOLUTIONS
12.2.1 HYPERSCALE CLOUD INFRASTRUCTURE ACCELERATES LIFE SCIENCE AI SCALABILITY AND COLLABORATIVE RESEARCH
12.3 ON-PREMISE SOLUTIONS
12.3.1 DATA SOVEREIGNTY AND GXP COMPLIANCE SUSTAIN ON-PREMISE AI DEPLOYMENT ACROSS REGULATED ENVIRONMENTS
12.4 HYBRID SOLUTIONS
12.4.1 HYBRID ARCHITECTURES BALANCE REGULATORY COMPLIANCE, DATA SECURITY, AND AI SCALABILITY DEMANDS
13 AI IN LIFE SCIENCE MARKET, BY END USER
13.1 INTRODUCTION
13.2 CRO & CDMO
13.2.1 AI-POWERED CROS & CDMOS COMPETE ON SPEED, QUALITY, AND DATA INTELLIGENCE DIFFERENTIATION
13.3 PHARMACEUTICAL COMPANIES
13.3.1 AI EMBEDDED ACROSS DISCOVERY, TRIALS, AND COMMERCIAL OPERATIONS BROADLY BY PHARMA LEADERS
13.4 BIOTECHNOLOGY COMPANIES
13.4.1 AI-NATIVE BIOTECH MODELS COMPRESSING DRUG DISCOVERY TIMELINES FROM YEARS TO MONTHS
13.5 DIAGNOSTIC COMPANIES
13.5.1 AI-AUGMENTED DIAGNOSTICS ELEVATE SENSITIVITY AND THROUGHPUT ACROSS MOLECULAR AND IMAGING PLATFORMS
13.6 ACADEMIC & GOVERNMENT LABORATORIES
13.6.1 PUBLIC AI RESEARCH PROGRAMS AND OPEN SCIENCE INITIATIVES BUILD FOUNDATIONAL LIFE SCIENCE INFRASTRUCTURE
13.7 OTHER END USERS
14 AI IN LIFE SCIENCE MARKET, BY OFFERING
14.1 INTRODUCTION
14.2 END-TO-END SOLUTION
14.2.1 INTEGRATED AI PLATFORMS COMPRESSING DRUG DEVELOPMENT TIMELINES ACROSS ENTIRE VALUE CHAINS
14.3 NICHE/POINT SOLUTIONS
14.3.1 DISEASE-SPECIFIC AI TOOLS DELIVER MEASURABLE OUTCOMES IN TARGETED RESEARCH WORKFLOWS
14.4 AI TECHNOLOGY
14.4.1 FOUNDATION MODELS AND GENERATIVE AI REDEFINE CORE SCIENTIFIC DISCOVERY CAPABILITIES
14.5 SERVICES
14.5.1 PROFESSIONAL AI SERVICES ENABLE COMPLIANT DEPLOYMENT ACROSS REGULATED LIFE SCIENCE ENVIRONMENTS
15 AI IN LIFE SCIENCE MARKET, BY REGION
15.1 INTRODUCTION
15.2 NORTH AMERICA
15.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA
15.2.2 US
15.2.2.1 Record FDA approvals and federal funding propel AI medical device commercialization
15.2.3 CANADA
15.2.3.1 Federal AI investment and sovereign compute strategy catalyze life sciences innovation
15.3 EUROPE
15.3.1 MACROECONOMIC OUTLOOK FOR EUROPE
15.3.2 GERMANY
15.3.2.1 Prescription digital health app framework propels market
15.3.3 FRANCE
15.3.3.1 National AI-health data strategy and health data hub anchor data-driven life sciences
15.3.4 UK
15.3.4.1 NHS Ten-Year Plan positions AI as core infrastructure for national care transformation
15.3.5 ITALY
15.3.5.1 National recovery plan digitization funding opens new hospital AI adoption pathways
15.3.6 SPAIN
15.3.6.1 National AI strategy and SNS digitization align life sciences sector with EU AI ambitions
15.3.7 REST OF EUROPE
15.4 ASIA PACIFIC
15.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC
15.4.2 CHINA
15.4.2.1 NMPA high-end device policy and AI standardization body streamline AI commercialization
15.4.3 JAPAN
15.4.3.1 PMDA adaptive AI framework and medical DX reforms accelerate SaMD commercialization
15.4.4 INDIA
15.4.4.1 IndiaAI mission and national health data infrastructure enable population-scale AI deployment
15.4.5 AUSTRALIA
15.4.5.1 My Health Record ecosystem and TGA SaMD pathways underpin AI-ready digital infrastructure
15.4.6 SOUTH KOREA
15.4.6.1 K-Medtech ecosystem and MFDS AI regulatory guidance propel smart hospital AI adoption
15.4.7 REST OF ASIA PACIFIC
15.5 LATIN AMERICA
15.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA
15.5.2 BRAZIL
15.5.2.1 RNDS National Health Network provides digital backbone for AI healthcare integration
15.5.3 MEXICO
15.5.3.1 IMSS digital transformation and National AI Strategy drive AI integration into public healthcare
15.5.4 REST OF LATIN AMERICA
15.6 MIDDLE EAST & AFRICA
15.6.1 MACROECONOMIC OUTLOOK FOR MIDDLE EAST & AFRICA
15.6.2 GCC
15.6.3 SAUDI ARABIA
15.6.3.1 Vision 2030 health sector transformation program drives AI-enabled care delivery at scale
15.6.4 UAE
15.6.4.1 Malaffi, NABIDH interoperability and Emirati Genome Programme establish AI-ready data foundation
15.6.5 REST OF GCC
15.6.5.1 Rising demand for telehealth & virtual care to propel market
15.6.6 SOUTH AFRICA
15.6.6.1 National health insurance framework and digital health programs catalyze AI market entry
15.6.7 REST OF MIDDLE EAST & AFRICA
16 COMPETITIVE LANDSCAPE
16.1 OVERVIEW
16.2 KEY PLAYER STRATEGIES/RIGHT TO WIN
16.2.1 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN AI IN LIFE SCIENCE MARKET
16.3 REVENUE ANALYSIS
16.4 MARKET SHARE ANALYSIS, 2025
16.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2025
16.5.1 STARS
16.5.2 EMERGING LEADERS
16.5.3 PERVASIVE PLAYERS
16.5.4 PARTICIPANTS
16.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2025
16.5.5.1 Company footprint
16.5.5.2 Region footprint
16.5.5.3 Offering footprint
16.5.5.4 Application footprint
16.5.5.5 End user footprint
16.5.5.6 Tools footprint
16.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2025
16.6.1 PROGRESSIVE COMPANIES
16.6.2 RESPONSIVE COMPANIES
16.6.3 DYNAMIC COMPANIES
16.6.4 STARTING BLOCKS
16.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2025
16.6.5.1 Detailed list of key startups/SMEs
16.6.5.2 Competitive benchmarking of startups/SMEs
16.7 VALUATION & FINANCIAL METRICS
16.7.1 FINANCIAL METRICS
16.7.2 COMPANY VALUATION
16.8 BRAND/SOFTWARE COMPARISON
16.9 COMPETITIVE SCENARIO
16.9.1 PRODUCT/SERVICE LAUNCHES & APPROVALS
16.9.2 DEALS
16.9.3 EXPANSIONS
17 COMPANY PROFILES
17.1 KEY PLAYERS
17.1.1 NVIDIA CORPORATION
17.1.1.1 Business overview
17.1.1.2 Products/Solutions offered
17.1.1.3 Recent developments
17.1.1.3.1 Product launches & enhancements
17.1.1.3.2 Deals
17.1.1.3.3 Other developments
17.1.1.4 MnM view
17.1.1.4.1 Key strengths
17.1.1.4.2 Strategic choices
17.1.1.4.3 Weaknesses and competitive threats
17.1.2 ILLUMINA, INC.
17.1.2.1 Business overview
17.1.2.2 Products/Solutions offered
17.1.2.3 Recent developments
17.1.2.3.1 Product launches & enhancements
17.1.2.3.2 Deals
17.1.2.4 MnM view
17.1.2.4.1 Key strengths
17.1.2.4.2 Strategic choices
17.1.2.4.3 Weaknesses and competitive threats
17.1.3 TEMPUS AI, INC.
17.1.3.1 Business overview
17.1.3.2 Products offered
17.1.3.3 Recent developments
17.1.3.3.1 Deals
17.1.3.3.2 Other developments
17.1.4 RECURSION
17.1.4.1 Business overview
17.1.4.2 Products/Solutions offered
17.1.4.3 Recent developments
17.1.4.3.1 Product launches & enhancements
17.1.4.3.2 Deals
17.1.4.3.3 Expansions
17.1.4.4 MnM view
17.1.4.4.1 Key strengths
17.1.4.4.2 Strategic choices
17.1.4.4.3 Weaknesses and competitive threats
17.1.5 DASSAULT SYST?MES SE
17.1.5.1 Business overview
17.1.5.2 Products offered
17.1.5.3 Recent developments
17.1.5.3.1 Product launches & enhancements
17.1.5.3.2 Deals
17.1.5.3.3 Other developments
17.1.6 SCHR?DINGER, INC.
17.1.6.1 Business overview
17.1.6.2 Products/Solutions offered
17.1.6.3 Recent developments
17.1.6.3.1 Deals
17.1.6.3.2 Other Developments
17.1.7 DATA4CURE, INC.
17.1.7.1 Business overview
17.1.7.2 Products offered
17.1.7.3 Recent developments
17.1.7.3.1 Product launches & enhancements
17.1.7.3.2 Other developments
17.1.8 MICROSOFT CORPORATION
17.1.8.1 Business overview
17.1.8.2 Products offered
17.1.8.3 Recent developments
17.1.8.3.1 Product launches & enhancements
17.1.8.3.2 Deals
17.1.8.3.3 Other developments
17.1.9 INSILICO MEDICINE
17.1.9.1 Business overview
17.1.9.2 Products/Services offered
17.1.9.3 Recent developments
17.1.9.3.1 Product launches & enhancements
17.1.9.3.2 Deals
17.1.9.3.3 Other developments
17.1.9.3.4 Expansions
17.1.10 EUROFINS DISCOVERY
17.1.10.1 Business overview
17.1.10.2 Products offered
17.1.10.3 Recent developments
17.1.10.3.1 Product launches & approvals
17.1.10.3.2 Deals
17.1.11 BENEVOLENTAI LIMITED
17.1.11.1 Business overview
17.1.11.2 Products offered
17.1.11.3 Recent developments
17.1.11.3.1 Deals
17.1.12 OWKIN
17.1.12.1 Business overview
17.1.12.2 Products offered
17.1.12.3 Recent developments
17.1.12.3.1 Product launches & approvals
17.1.12.3.2 Deals
17.1.12.3.3 Other developments
17.1.13 PATHAI
17.1.13.1 Business overview
17.1.13.2 Products offered
17.1.13.3 Recent developments
17.1.13.3.1 Product launches & approvals
17.1.13.3.2 Deals
17.1.14 AIDOC MEDICAL LTD.
17.1.14.1 Business overview
17.1.14.2 Products offered
17.1.14.3 Recent developments
17.1.14.3.1 Product launches & approvals
17.1.14.3.2 Other developments
17.1.15 QURE.AI
17.1.15.1 Business overview
17.1.15.2 Products offered
17.1.15.3 Recent developments
17.1.15.3.1 Product launches & approvals
17.1.16 DEEP GENOMICS
17.1.16.1 Business overview
17.1.16.2 Products offered
17.1.16.3 Recent developments
17.1.16.3.1 Expansions
17.1.17 SOPHIA GENETICS SA
17.1.17.1 Business overview
17.1.17.2 Products offered
17.1.17.3 Recent developments
17.1.17.3.1 Product launches & enhancements
17.1.17.3.2 Deals
17.1.18 UNLEARN.AI
17.1.18.1 Business overview
17.1.18.2 Products offered
17.1.18.3 Recent developments
17.1.18.3.1 Deals
17.1.19 VERGE GENOMICS
17.1.19.1 Business overview
17.1.19.2 Products offered
17.1.19.3 Recent developments
17.1.19.3.1 Deals
17.2 OTHER PLAYERS
17.2.1 SYNTHIO LABS LTD
17.2.2 BIOPTIMUS
17.2.3 KARYON BIO
17.2.4 COUNTERFORCE HEALTH
17.2.5 PROMISE BIO
18 RESEARCH METHODOLOGY
18.1 RESEARCH APPROACH
18.1.1 SECONDARY RESEARCH
18.1.1.1 Key data from secondary sources
18.1.2 PRIMARY RESEARCH
18.1.2.1 Primary sources
18.1.2.2 Key data from primary sources
18.1.2.3 Breakdown of primary interviews
18.1.2.4 Insights from primary experts
18.2 RESEARCH METHODOLOGY DESIGN
18.3 MARKET SIZE ESTIMATION
18.4 DATA TRIANGULATION
18.5 RESEARCH ASSUMPTIONS
18.6 RESEARCH LIMITATIONS
18.6.1 METHODOLOGY-RELATED
18.6.2 SCOPE-RELATED
18.7 RISK ASSESSMENT
19 APPENDIX
19.1 DISCUSSION GUIDE
19.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
19.3 CUSTOMIZATION OPTIONS
19.4 RELATED REPORTS:
19.5 AUTHOR DETAILS
1.1 STUDY OBJECTIVES
1.2 MARKET DEFINITION
1.3 STUDY SCOPE
1.3.1 MARKET SEGMENTATION AND REGIONAL SCOPE
1.3.2 INCLUSIONS AND EXCLUSIONS
1.3.3 YEARS CONSIDERED
1.4 CURRENCY CONSIDERED
1.5 STAKEHOLDERS
2 EXECUTIVE SUMMARY
2.1 KEY INSIGHTS AND MARKET HIGHLIGHTS
2.2 KEY MARKET PARTICIPANTS: SHARE INSIGHTS AND STRATEGIC DEVELOPMENTS
2.3 DISRUPTIVE TRENDS SHAPING THE MARKET
2.4 HIGH-GROWTH SEGMENTS & EMERGING FRONTIERS
2.5 SNAPSHOT: GLOBAL MARKET SIZE, GROWTH RATE, AND FORECAST
3 PREMIUM INSIGHTS
3.1 AI IN LIFE SCIENCE MARKET OVERVIEW
3.2 AI IN LIFE SCIENCE MARKET, BY APPLICATION & REGION
3.3 AI IN LIFE SCIENCE MARKET: REGIONAL SNAPSHOT
4 MARKET OVERVIEW
4.1 INTRODUCTION
4.2 MARKET DYNAMICS
4.2.1 DRIVERS
4.2.1.1 Surging demand for accelerated drug discovery and R&D pipeline optimization
4.2.1.2 Growing cross-industry partnerships
4.2.1.3 Expanding applications of AI in clinical trial design, patient recruitment, and operational efficiency
4.2.1.4 Growing availability of large-scale biomedical datasets and advances in computing infrastructure
4.2.1.5 Supportive government policies, funding initiatives, and regulatory frameworks
4.2.2 RESTRAINTS
4.2.2.1 Data privacy and cybersecurity concerns
4.2.2.2 Algorithmic bias and clinician trust deficits
4.2.2.3 High implementation costs, technical complexity, and integration challenges with legacy IT systems
4.2.3 OPPORTUNITIES
4.2.3.1 Generative AI and foundation models for de novo drug design
4.2.3.2 Rising focus on rare disease treatments
4.2.3.3 Growing demand for precision and personalized medicine
4.2.3.4 AI integration in academic research institutes and government-backed biomedical innovation programs
4.2.4 CHALLENGES
4.2.4.1 Low data fragmentation, interoperability deficits
4.2.4.2 Talent scarcity and organizational readiness
4.3 UNMET NEEDS AND WHITE SPACES
4.4 INTERCONNECTED MARKETS AND CROSS-SECTOR OPPORTUNITIES
4.5 STRATEGIC MOVES BY TIER-1/2/3 PLAYERS
5 INDUSTRY TRENDS
5.1 PORTER’S FIVE FORCES ANALYSIS
5.1.1 BARGAINING POWER OF SUPPLIERS
5.1.2 BARGAINING POWER OF BUYERS
5.1.3 THREAT OF SUBSTITUTES
5.1.4 THREAT OF NEW ENTRANTS
5.1.5 INTENSITY OF COMPETITIVE RIVALRY
5.2 MACROECONOMIC INDICATORS
5.2.1 INTRODUCTION
5.2.2 GDP TRENDS AND FORECAST
5.2.3 TRENDS IN GLOBAL HEALTHCARE IT INDUSTRY
5.3 VALUE CHAIN ANALYSIS
5.4 ECOSYSTEM ANALYSIS
5.5 PRICING ANALYSIS
5.5.1 INDICATIVE PRICE FOR AI IN LIFE SCIENCE MARKET (2025)
5.5.2 INDICATIVE PRICE FOR AI IN LIFE SCIENCE MARKET, BY REGION (2025)
5.6 KEY CONFERENCES AND EVENTS, 2026–2027
5.7 TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS
5.8 INVESTMENT AND FUNDING SCENARIO
5.9 CASE STUDY ANALYSIS
5.10 IMPACT OF 2025 US TARIFF – AI IN LIFE SCIENCE MARKET
5.10.1 INTRODUCTION
5.10.2 KEY TARIFF RATES
5.10.3 PRICE IMPACT ANALYSIS
5.10.4 IMPACT ON COUNTRY/REGION
5.10.4.1 US
5.10.4.2 Europe
5.10.4.3 Asia Pacific
5.10.5 IMPACT ON END USERS
5.10.5.1 CRO & CDMO
5.10.5.2 Pharmaceutical & biotechnology companies
5.10.5.3 Research centers & academic institutes
5.10.5.4 Diagnostic companies
6 REGULATORY LANDSCAPE
6.1 REGIONAL REGULATIONS AND COMPLIANCE
6.1.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
6.1.2 NORTH AMERICA
6.1.3 EUROPE
6.1.4 ASIA PACIFIC
6.1.5 MIDDLE EAST & AFRICA
6.1.6 LATIN AMERICA
6.1.7 INDUSTRY STANDARDS
7 STRATEGIC DISRUPTION THROUGH TECHNOLOGY, PATENTS, DIGITAL, AND AI ADOPTION
7.1 KEY EMERGING TECHNOLOGIES
7.1.1 GRAPH NEURAL NETWORKS
7.1.2 COMPUTER VISION
7.1.3 PREDICTIVE ANALYTICS
7.2 COMPLEMENTARY TECHNOLOGIES
7.2.1 NEXT-GENERATION SEQUENCING
7.2.2 REAL-WORLD EVIDENCE/REAL-WORLD DATA
7.2.3 PERSONALIZATION ENGINES
7.3 ADJACENT TECHNOLOGIES
7.3.1 CLOUD COMPUTING
7.3.2 BLOCKCHAIN
7.3.3 BIG DATA & ADVANCED ANALYTICS
7.4 TECHNOLOGY/PRODUCT ROADMAP
7.5 PATENT ANALYSIS
7.5.1 INSIGHTS: JURISDICTION AND TOP APPLICANT ANALYSIS
7.6 FUTURE APPLICATIONS
7.6.1 AI-DRIVEN DRUG DISCOVERY
7.6.2 GENOMIC ANALYSIS
7.6.3 PRECISION MEDICINE
7.6.4 VIRTUAL DRUG SCREENING
8 CUSTOMER LANDSCAPE & BUYER BEHAVIOR
8.1 INTRODUCTION
8.2 DECISION-MAKING PROCESS
8.3 BUYER STAKEHOLDERS AND BUYING EVALUATION CRITERIA
8.3.1 KEY STAKEHOLDERS IN BUYING PROCESS
8.3.2 BUYING CRITERIA
8.4 ADOPTION BARRIERS & INTERNAL CHALLENGES
8.5 UNMET NEEDS FROM VARIOUS END-USE INDUSTRIES
8.5.1 UNMET NEEDS
8.5.2 END USER EXPECTATIONS
8.6 MARKET PROFITABILITY
9 AI IN LIFE SCIENCE MARKET, BY TOOL
9.1 INTRODUCTION
9.2 MACHINE LEARNING
9.2.1 DEEP LEARNING
9.2.1.1 Convolutional neural networks
9.2.1.1.1 High-sensitivity medical imaging AI across oncology and radiology pathways – key driver
9.2.1.2 Recurrent neural networks
9.2.1.2.1 Sequential biological data processing drives adoption in clinical and genomic applications
9.2.1.3 Generative adversarial networks
9.2.1.3.1 Synthetic data generation to overcome life science data scarcity barriers boosts adoption
9.2.1.4 Graph neural networks
9.2.1.4.1 Graph AI architectures modeling molecular interactions to advance target and pathway discovery
9.2.1.5 Others
9.2.1.5.1 Transformer and diffusion architectures expanding deep learning frontiers in life sciences
9.2.2 SUPERVISED LEARNING
9.2.2.1 Segment driven by accurate prediction of compound potency and selectivity across diverse chemical series
9.2.3 REINFORCEMENT LEARNING
9.2.3.1 Optimized drug dosing, trial design, and autonomous laboratory systems to drive segment
9.2.4 UNSUPERVISED LEARNING
9.2.4.1 Unsupervised AI revealing hidden biological patterns within high-dimensional omics datasets
9.2.5 OTHER MACHINE LEARNING TECHNOLOGIES
9.2.5.1 Semi-supervised and federated learning overcome data scarcity and privacy constraints
9.3 NATURAL LANGUAGE PROCESSING
9.3.1 BIOMEDICAL LLMS AND CLINICAL NLP AUTOMATING KNOWLEDGE EXTRACTION FROM UNSTRUCTURED HEALTH DATA
9.4 CONTEXT-AWARE PROCESSING AND COMPUTING
9.4.1 SEGMENT DRIVEN BY DYNAMIC, PATIENT-SPECIFIC INSIGHTS ACROSS CLINICAL WORKFLOWS
9.5 COMPUTER VISION
9.5.1 TRANSFORMATION OF PATHOLOGY, DERMATOLOGY, AND DRUG MANUFACTURING INSPECTION PROCESSES – KEY DRIVERS
9.6 IMAGE ANALYSIS
9.6.1 ACCELERATED DIGITAL PATHOLOGY, LAB IMAGING, AND DOCUMENT PROCESSING TO BOOST ADOPTION
9.7 OTHER TOOLS
10 AI IN LIFE SCIENCE MARKET, BY APPLICATION
10.1 INTRODUCTION
10.2 CLINICAL APPLICATIONS
10.2.1 REDUCED DEVELOPMENT TIMELINES AND IMPROVED CLINICAL SUCCESS TO DRIVE SEGMENT
10.2.2 DRUG DISCOVERY
10.2.2.1 AI-driven target identification transforming biopharma R&D productivity and success rates
10.2.3 MEDICAL IMAGING & DIAGNOSTICS
10.2.3.1 Accelerating FDA clearances and radiology digitization drives clinical AI imaging adoption
10.2.4 CLINICAL TRIALS
10.2.4.1 AI-powered trial optimization and decentralized models accelerating patient-centric research
10.2.5 PRECISION MEDICINE
10.2.5.1 Multi-Omics AI integration enabling individualized therapy selection at population scale
10.2.6 OTHER CLINICAL APPLICATIONS
10.2.6.1 AI-augmented clinical decision support expanding into pharmacovigilance and rare disease
10.3 NON-CLINICAL APPLICATIONS
10.3.1 R&D SUPPORT
10.3.1.1 AI-enabled literature mining and lab automation multiplying R&D throughput significantly
10.3.2 DATA ANALYTICS & REPORTING
10.3.2.1 Real-world evidence and AI analytics transforming strategic decision-making across organizations
10.3.3 MANUFACTURING & QUALITY ASSURANCE
10.3.3.1 Predictive quality AI and continuous manufacturing reduce batch failures and compliance risk
10.3.4 REGULATORY AFFAIRS
10.3.4.1 FDA and EMA AI guidance catalyzing regulatory submission automation and pharmacovigilance efficiency
11 AI IN LIFE SCIENCE MARKET, BY COMPONENT
11.1 INTRODUCTION
11.2 SOFTWARE
11.2.1 AI SOFTWARE PLATFORMS BECOMING CORE INFRASTRUCTURE FOR LIFE SCIENCE DIGITAL TRANSFORMATION
11.3 SERVICE
11.3.1 SPECIALIZED AI SERVICES BRIDGING VALIDATION AND COMPLIANCE GAPS ACROSS LIFE SCIENCE ENTERPRISES
12 AI IN LIFE SCIENCE MARKET, BY DEPLOYMENT
12.1 INTRODUCTION
12.2 CLOUD-BASED SOLUTIONS
12.2.1 HYPERSCALE CLOUD INFRASTRUCTURE ACCELERATES LIFE SCIENCE AI SCALABILITY AND COLLABORATIVE RESEARCH
12.3 ON-PREMISE SOLUTIONS
12.3.1 DATA SOVEREIGNTY AND GXP COMPLIANCE SUSTAIN ON-PREMISE AI DEPLOYMENT ACROSS REGULATED ENVIRONMENTS
12.4 HYBRID SOLUTIONS
12.4.1 HYBRID ARCHITECTURES BALANCE REGULATORY COMPLIANCE, DATA SECURITY, AND AI SCALABILITY DEMANDS
13 AI IN LIFE SCIENCE MARKET, BY END USER
13.1 INTRODUCTION
13.2 CRO & CDMO
13.2.1 AI-POWERED CROS & CDMOS COMPETE ON SPEED, QUALITY, AND DATA INTELLIGENCE DIFFERENTIATION
13.3 PHARMACEUTICAL COMPANIES
13.3.1 AI EMBEDDED ACROSS DISCOVERY, TRIALS, AND COMMERCIAL OPERATIONS BROADLY BY PHARMA LEADERS
13.4 BIOTECHNOLOGY COMPANIES
13.4.1 AI-NATIVE BIOTECH MODELS COMPRESSING DRUG DISCOVERY TIMELINES FROM YEARS TO MONTHS
13.5 DIAGNOSTIC COMPANIES
13.5.1 AI-AUGMENTED DIAGNOSTICS ELEVATE SENSITIVITY AND THROUGHPUT ACROSS MOLECULAR AND IMAGING PLATFORMS
13.6 ACADEMIC & GOVERNMENT LABORATORIES
13.6.1 PUBLIC AI RESEARCH PROGRAMS AND OPEN SCIENCE INITIATIVES BUILD FOUNDATIONAL LIFE SCIENCE INFRASTRUCTURE
13.7 OTHER END USERS
14 AI IN LIFE SCIENCE MARKET, BY OFFERING
14.1 INTRODUCTION
14.2 END-TO-END SOLUTION
14.2.1 INTEGRATED AI PLATFORMS COMPRESSING DRUG DEVELOPMENT TIMELINES ACROSS ENTIRE VALUE CHAINS
14.3 NICHE/POINT SOLUTIONS
14.3.1 DISEASE-SPECIFIC AI TOOLS DELIVER MEASURABLE OUTCOMES IN TARGETED RESEARCH WORKFLOWS
14.4 AI TECHNOLOGY
14.4.1 FOUNDATION MODELS AND GENERATIVE AI REDEFINE CORE SCIENTIFIC DISCOVERY CAPABILITIES
14.5 SERVICES
14.5.1 PROFESSIONAL AI SERVICES ENABLE COMPLIANT DEPLOYMENT ACROSS REGULATED LIFE SCIENCE ENVIRONMENTS
15 AI IN LIFE SCIENCE MARKET, BY REGION
15.1 INTRODUCTION
15.2 NORTH AMERICA
15.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA
15.2.2 US
15.2.2.1 Record FDA approvals and federal funding propel AI medical device commercialization
15.2.3 CANADA
15.2.3.1 Federal AI investment and sovereign compute strategy catalyze life sciences innovation
15.3 EUROPE
15.3.1 MACROECONOMIC OUTLOOK FOR EUROPE
15.3.2 GERMANY
15.3.2.1 Prescription digital health app framework propels market
15.3.3 FRANCE
15.3.3.1 National AI-health data strategy and health data hub anchor data-driven life sciences
15.3.4 UK
15.3.4.1 NHS Ten-Year Plan positions AI as core infrastructure for national care transformation
15.3.5 ITALY
15.3.5.1 National recovery plan digitization funding opens new hospital AI adoption pathways
15.3.6 SPAIN
15.3.6.1 National AI strategy and SNS digitization align life sciences sector with EU AI ambitions
15.3.7 REST OF EUROPE
15.4 ASIA PACIFIC
15.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC
15.4.2 CHINA
15.4.2.1 NMPA high-end device policy and AI standardization body streamline AI commercialization
15.4.3 JAPAN
15.4.3.1 PMDA adaptive AI framework and medical DX reforms accelerate SaMD commercialization
15.4.4 INDIA
15.4.4.1 IndiaAI mission and national health data infrastructure enable population-scale AI deployment
15.4.5 AUSTRALIA
15.4.5.1 My Health Record ecosystem and TGA SaMD pathways underpin AI-ready digital infrastructure
15.4.6 SOUTH KOREA
15.4.6.1 K-Medtech ecosystem and MFDS AI regulatory guidance propel smart hospital AI adoption
15.4.7 REST OF ASIA PACIFIC
15.5 LATIN AMERICA
15.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA
15.5.2 BRAZIL
15.5.2.1 RNDS National Health Network provides digital backbone for AI healthcare integration
15.5.3 MEXICO
15.5.3.1 IMSS digital transformation and National AI Strategy drive AI integration into public healthcare
15.5.4 REST OF LATIN AMERICA
15.6 MIDDLE EAST & AFRICA
15.6.1 MACROECONOMIC OUTLOOK FOR MIDDLE EAST & AFRICA
15.6.2 GCC
15.6.3 SAUDI ARABIA
15.6.3.1 Vision 2030 health sector transformation program drives AI-enabled care delivery at scale
15.6.4 UAE
15.6.4.1 Malaffi, NABIDH interoperability and Emirati Genome Programme establish AI-ready data foundation
15.6.5 REST OF GCC
15.6.5.1 Rising demand for telehealth & virtual care to propel market
15.6.6 SOUTH AFRICA
15.6.6.1 National health insurance framework and digital health programs catalyze AI market entry
15.6.7 REST OF MIDDLE EAST & AFRICA
16 COMPETITIVE LANDSCAPE
16.1 OVERVIEW
16.2 KEY PLAYER STRATEGIES/RIGHT TO WIN
16.2.1 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN AI IN LIFE SCIENCE MARKET
16.3 REVENUE ANALYSIS
16.4 MARKET SHARE ANALYSIS, 2025
16.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2025
16.5.1 STARS
16.5.2 EMERGING LEADERS
16.5.3 PERVASIVE PLAYERS
16.5.4 PARTICIPANTS
16.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2025
16.5.5.1 Company footprint
16.5.5.2 Region footprint
16.5.5.3 Offering footprint
16.5.5.4 Application footprint
16.5.5.5 End user footprint
16.5.5.6 Tools footprint
16.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2025
16.6.1 PROGRESSIVE COMPANIES
16.6.2 RESPONSIVE COMPANIES
16.6.3 DYNAMIC COMPANIES
16.6.4 STARTING BLOCKS
16.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2025
16.6.5.1 Detailed list of key startups/SMEs
16.6.5.2 Competitive benchmarking of startups/SMEs
16.7 VALUATION & FINANCIAL METRICS
16.7.1 FINANCIAL METRICS
16.7.2 COMPANY VALUATION
16.8 BRAND/SOFTWARE COMPARISON
16.9 COMPETITIVE SCENARIO
16.9.1 PRODUCT/SERVICE LAUNCHES & APPROVALS
16.9.2 DEALS
16.9.3 EXPANSIONS
17 COMPANY PROFILES
17.1 KEY PLAYERS
17.1.1 NVIDIA CORPORATION
17.1.1.1 Business overview
17.1.1.2 Products/Solutions offered
17.1.1.3 Recent developments
17.1.1.3.1 Product launches & enhancements
17.1.1.3.2 Deals
17.1.1.3.3 Other developments
17.1.1.4 MnM view
17.1.1.4.1 Key strengths
17.1.1.4.2 Strategic choices
17.1.1.4.3 Weaknesses and competitive threats
17.1.2 ILLUMINA, INC.
17.1.2.1 Business overview
17.1.2.2 Products/Solutions offered
17.1.2.3 Recent developments
17.1.2.3.1 Product launches & enhancements
17.1.2.3.2 Deals
17.1.2.4 MnM view
17.1.2.4.1 Key strengths
17.1.2.4.2 Strategic choices
17.1.2.4.3 Weaknesses and competitive threats
17.1.3 TEMPUS AI, INC.
17.1.3.1 Business overview
17.1.3.2 Products offered
17.1.3.3 Recent developments
17.1.3.3.1 Deals
17.1.3.3.2 Other developments
17.1.4 RECURSION
17.1.4.1 Business overview
17.1.4.2 Products/Solutions offered
17.1.4.3 Recent developments
17.1.4.3.1 Product launches & enhancements
17.1.4.3.2 Deals
17.1.4.3.3 Expansions
17.1.4.4 MnM view
17.1.4.4.1 Key strengths
17.1.4.4.2 Strategic choices
17.1.4.4.3 Weaknesses and competitive threats
17.1.5 DASSAULT SYST?MES SE
17.1.5.1 Business overview
17.1.5.2 Products offered
17.1.5.3 Recent developments
17.1.5.3.1 Product launches & enhancements
17.1.5.3.2 Deals
17.1.5.3.3 Other developments
17.1.6 SCHR?DINGER, INC.
17.1.6.1 Business overview
17.1.6.2 Products/Solutions offered
17.1.6.3 Recent developments
17.1.6.3.1 Deals
17.1.6.3.2 Other Developments
17.1.7 DATA4CURE, INC.
17.1.7.1 Business overview
17.1.7.2 Products offered
17.1.7.3 Recent developments
17.1.7.3.1 Product launches & enhancements
17.1.7.3.2 Other developments
17.1.8 MICROSOFT CORPORATION
17.1.8.1 Business overview
17.1.8.2 Products offered
17.1.8.3 Recent developments
17.1.8.3.1 Product launches & enhancements
17.1.8.3.2 Deals
17.1.8.3.3 Other developments
17.1.9 INSILICO MEDICINE
17.1.9.1 Business overview
17.1.9.2 Products/Services offered
17.1.9.3 Recent developments
17.1.9.3.1 Product launches & enhancements
17.1.9.3.2 Deals
17.1.9.3.3 Other developments
17.1.9.3.4 Expansions
17.1.10 EUROFINS DISCOVERY
17.1.10.1 Business overview
17.1.10.2 Products offered
17.1.10.3 Recent developments
17.1.10.3.1 Product launches & approvals
17.1.10.3.2 Deals
17.1.11 BENEVOLENTAI LIMITED
17.1.11.1 Business overview
17.1.11.2 Products offered
17.1.11.3 Recent developments
17.1.11.3.1 Deals
17.1.12 OWKIN
17.1.12.1 Business overview
17.1.12.2 Products offered
17.1.12.3 Recent developments
17.1.12.3.1 Product launches & approvals
17.1.12.3.2 Deals
17.1.12.3.3 Other developments
17.1.13 PATHAI
17.1.13.1 Business overview
17.1.13.2 Products offered
17.1.13.3 Recent developments
17.1.13.3.1 Product launches & approvals
17.1.13.3.2 Deals
17.1.14 AIDOC MEDICAL LTD.
17.1.14.1 Business overview
17.1.14.2 Products offered
17.1.14.3 Recent developments
17.1.14.3.1 Product launches & approvals
17.1.14.3.2 Other developments
17.1.15 QURE.AI
17.1.15.1 Business overview
17.1.15.2 Products offered
17.1.15.3 Recent developments
17.1.15.3.1 Product launches & approvals
17.1.16 DEEP GENOMICS
17.1.16.1 Business overview
17.1.16.2 Products offered
17.1.16.3 Recent developments
17.1.16.3.1 Expansions
17.1.17 SOPHIA GENETICS SA
17.1.17.1 Business overview
17.1.17.2 Products offered
17.1.17.3 Recent developments
17.1.17.3.1 Product launches & enhancements
17.1.17.3.2 Deals
17.1.18 UNLEARN.AI
17.1.18.1 Business overview
17.1.18.2 Products offered
17.1.18.3 Recent developments
17.1.18.3.1 Deals
17.1.19 VERGE GENOMICS
17.1.19.1 Business overview
17.1.19.2 Products offered
17.1.19.3 Recent developments
17.1.19.3.1 Deals
17.2 OTHER PLAYERS
17.2.1 SYNTHIO LABS LTD
17.2.2 BIOPTIMUS
17.2.3 KARYON BIO
17.2.4 COUNTERFORCE HEALTH
17.2.5 PROMISE BIO
18 RESEARCH METHODOLOGY
18.1 RESEARCH APPROACH
18.1.1 SECONDARY RESEARCH
18.1.1.1 Key data from secondary sources
18.1.2 PRIMARY RESEARCH
18.1.2.1 Primary sources
18.1.2.2 Key data from primary sources
18.1.2.3 Breakdown of primary interviews
18.1.2.4 Insights from primary experts
18.2 RESEARCH METHODOLOGY DESIGN
18.3 MARKET SIZE ESTIMATION
18.4 DATA TRIANGULATION
18.5 RESEARCH ASSUMPTIONS
18.6 RESEARCH LIMITATIONS
18.6.1 METHODOLOGY-RELATED
18.6.2 SCOPE-RELATED
18.7 RISK ASSESSMENT
19 APPENDIX
19.1 DISCUSSION GUIDE
19.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
19.3 CUSTOMIZATION OPTIONS
19.4 RELATED REPORTS:
19.5 AUTHOR DETAILS
LIST OF TABLES
TABLE 1 EXCHANGE RATES UTILIZED FOR CONVERSION TO USD
TABLE 2 AI IN LIFE SCIENCE MARKET: PORTER’S FIVE FORCES ANALYSIS
TABLE 3 AI IN LIFE SCIENCE MARKET: ROLE IN ECOSYSTEM
TABLE 4 CASE 1: GENERATIVE AI ACCELERATES DRUG DISCOVERY, CLINICAL RESEARCH, AND OPERATIONAL EFFICIENCY IN LIFE SCIENCES
TABLE 5 CASE 2: JOHNSON & JOHNSON EXPANDS AI INTEGRATION ACROSS DRUG DISCOVERY, SURGICAL INNOVATION, AND HEALTHCARE OPERATIONS
TABLE 6 CASE 3: AI-DRIVEN DRUG DISCOVERY AND CLINICAL OPTIMIZATION ACCELERATE INNOVATION IN LIFE SCIENCES
TABLE 7 US ADJUSTED RECIPROCAL TARIFF RATES
TABLE 8 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 9 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 10 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 11 LATIN AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 12 MIDDLE EAST & AFRICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 13 JURISDICTION ANALYSIS OF TOP APPLICANT COUNTRIES FOR AI IN LIFE SCIENCE MARKET
TABLE 14 AI IN LIFE SCIENCE MARKET: KEY PATENTS/PATENT APPLICATIONS
TABLE 15 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF TOP THREE END USERS (%)
TABLE 16 KEY BUYING CRITERIA FOR TOP THREE END USERS
TABLE 17 UNMET NEEDS IN AI IN LIFE SCIENCE MARKET
TABLE 18 END USER EXPECTATIONS IN AI IN LIFE SCIENCE MARKET
TABLE 19 AI IN LIFE SCIENCE MARKET, BY TOOL, 2024–2031 (USD MILLION)
TABLE 20 AI IN LIFE SCIENCE MARKET FOR MACHINE LEARNING, BY TYPE, 2024–2031 (USD MILLION)
TABLE 21 AI IN LIFE SCIENCE MARKET FOR MACHINE LEARNING, BY REGION, 2024–2031 (USD MILLION)
TABLE 22 AI IN LIFE SCIENCE MARKET FOR DEEP LEARNING, BY TYPE, 2024–2031 (USD MILLION)
TABLE 23 AI IN LIFE SCIENCE MARKET FOR DEEP LEARNING, BY REGION, 2024–2031 (USD MILLION)
TABLE 24 AI IN LIFE SCIENCE MARKET FOR CONVOLUTIONAL NEURAL NETWORKS, BY REGION, 2024–2031 (USD MILLION)
TABLE 25 AI IN LIFE SCIENCE MARKET FOR RECURRENT NEURAL NETWORKS, BY REGION, 2024–2031 (USD MILLION)
TABLE 26 AI IN LIFE SCIENCE MARKET FOR GENERATIVE ADVERSARIAL NETWORKS, BY REGION, 2024–2031 (USD MILLION)
TABLE 27 AI IN LIFE SCIENCE MARKET FOR GRAPH NEURAL NETWORKS, BY REGION, 2024–2031 (USD MILLION)
TABLE 28 AI IN LIFE SCIENCE MARKET FOR OTHER DEEP LEARNING TOOLS, BY REGION, 2024–2031 (USD MILLION)
TABLE 29 AI IN LIFE SCIENCE MARKET FOR SUPERVISED LEARNING, BY REGION, 2024–2031 (USD MILLION)
TABLE 30 AI IN LIFE SCIENCE MARKET FOR REINFORCEMENT LEARNING, BY REGION, 2024–2031 (USD MILLION)
TABLE 31 AI IN LIFE SCIENCE MARKET FOR UNSUPERVISED LEARNING, BY REGION, 2024–2031 (USD MILLION)
TABLE 32 AI IN LIFE SCIENCE MARKET FOR OTHER MACHINE LEARNING TECHNOLOGIES, BY REGION, 2024–2031 (USD MILLION)
TABLE 33 AI IN LIFE SCIENCE MARKET FOR NATURAL LANGUAGE PROCESSING, BY REGION, 2024–2031 (USD MILLION)
TABLE 34 AI IN LIFE SCIENCE MARKET FOR CONTEXT-AWARE PROCESSING AND COMPUTING, BY REGION, 2024–2031 (USD MILLION)
TABLE 35 AI IN LIFE SCIENCE MARKET FOR COMPUTER VISION, BY REGION, 2024–2031 (USD MILLION)
TABLE 36 AI IN LIFE SCIENCE MARKET FOR IMAGE ANALYSIS, BY REGION, 2024–2031 (USD MILLION)
TABLE 37 AI IN LIFE SCIENCE MARKET FOR OTHER TOOLS, BY REGION, 2024–2031 (USD MILLION)
TABLE 38 AI IN LIFE SCIENCE MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
TABLE 39 AI IN LIFE SCIENCE MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2024–2031 (USD MILLION)
TABLE 40 AI IN LIFE SCIENCE MARKET FOR CLINICAL APPLICATIONS, BY REGION, 2024–2031 (USD MILLION)
TABLE 41 AI IN LIFE SCIENCE MARKET FOR DRUG DISCOVERY, BY REGION, 2024–2031 (USD MILLION)
TABLE 42 AI IN LIFE SCIENCE MARKET FOR MEDICAL IMAGING AND DIAGNOSTICS, BY REGION, 2024–2031 (USD MILLION)
TABLE 43 AI IN LIFE SCIENCE MARKET FOR CLINICAL TRIALS, BY REGION, 2024–2031 (USD MILLION)
TABLE 44 AI IN LIFE SCIENCE MARKET FOR PRECISION MEDICINE, BY REGION, 2024–2031 (USD MILLION)
TABLE 45 AI IN LIFE SCIENCE MARKET FOR OTHER CLINICAL APPLICATIONS, BY REGION, 2024–2031 (USD MILLION)
TABLE 46 AI IN LIFE SCIENCE MARKET FOR NON-CLINICAL APPLICATIONS, BY TYPE, 2024–2031 (USD MILLION)
TABLE 47 AI IN LIFE SCIENCE MARKET FOR NON-CLINICAL APPLICATIONS, BY REGION, 2024–2031 (USD MILLION)
TABLE 48 AI IN LIFE SCIENCE MARKET FOR R&D SUPPORT, BY REGION, 2024–2031 (USD MILLION)
TABLE 49 AI IN LIFE SCIENCE MARKET FOR DATA ANALYTICS AND REPORTING, BY REGION, 2024–2031 (USD MILLION)
TABLE 50 AI IN LIFE SCIENCE MARKET FOR MANUFACTURING & QUALITY ASSURANCE, BY REGION, 2024–2031 (USD MILLION)
TABLE 51 AI IN LIFE SCIENCE MARKET FOR REGULATORY AFFAIRS, BY REGION, 2024–2031 (USD MILLION)
TABLE 52 AI IN LIFE SCIENCE MARKET, BY COMPONENT, 2024–2031 (USD MILLION)
TABLE 53 AI IN LIFE SCIENCE MARKET FOR SOFTWARE, BY REGION, 2024–2031 (USD MILLION)
TABLE 54 AI IN LIFE SCIENCE MARKET FOR SERVICE, BY REGION, 2024–2031 (USD MILLION)
TABLE 55 AI IN LIFE SCIENCE MARKET, BY DEPLOYMENT, 2024–2031 (USD MILLION)
TABLE 56 AI IN LIFE SCIENCE MARKET FOR CLOUD-BASED SOLUTIONS, BY REGION, 2024–2031 (USD MILLION)
TABLE 57 AI IN LIFE SCIENCE MARKET FOR ON-PREMISE SOLUTIONS, BY REGION, 2024–2031 (USD MILLION)
TABLE 58 AI IN LIFE SCIENCE MARKET FOR HYBRID SOLUTIONS, BY REGION, 2024–2031 (USD MILLION)
TABLE 59 AI IN LIFE SCIENCE MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 60 AI IN LIFE SCIENCE MARKET FOR CRO & CDMO, BY REGION, 2024–2031 (USD MILLION)
TABLE 61 AI IN LIFE SCIENCE MARKET FOR PHARMACEUTICAL COMPANIES, BY REGION, 2024–2031 (USD MILLION)
TABLE 62 AI IN LIFE SCIENCE MARKET FOR BIOTECHNOLOGY COMPANIES, BY REGION, 2024–2031 (USD MILLION)
TABLE 63 AI IN LIFE SCIENCE MARKET FOR DIAGNOSTIC COMPANIES, BY REGION, 2024–2031 (USD MILLION)
TABLE 64 AI IN LIFE SCIENCE MARKET FOR ACADEMIC AND GOVERNMENT LABORATORIES, BY REGION, 2024–2031 (USD MILLION)
TABLE 65 AI IN LIFE SCIENCE MARKET FOR OTHER END USERS, BY REGION, 2024–2031 (USD MILLION)
TABLE 66 AI IN LIFE SCIENCE MARKET, BY OFFERING, 2024–2031 (USD MILLION)
TABLE 67 AI IN LIFE SCIENCE MARKET FOR END-TO-END SOLUTIONS, BY REGION, 2024–2031 (USD MILLION)
TABLE 68 AI IN LIFE SCIENCE MARKET FOR NICHE/POINT SOLUTIONS, BY REGION, 2024–2031 (USD MILLION)
TABLE 69 AI IN LIFE SCIENCE MARKET FOR AI TECHNOLOGY, BY REGION, 2024–2031 (USD MILLION)
TABLE 70 AI IN LIFE SCIENCE MARKET FOR SERVICES, BY REGION, 2024–2031 (USD MILLION)
TABLE 71 AI IN LIFE SCIENCE MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 72 NORTH AMERICA: AI IN LIFE SCIENCE MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 73 NORTH AMERICA: AI IN LIFE SCIENCE MARKET, BY OFFERING, 2024–2031 (USD MILLION)
TABLE 74 NORTH AMERICA: AI IN LIFE SCIENCE MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
TABLE 75 NORTH AMERICA: AI IN LIFE SCIENCE MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2024–2031 (USD MILLION)
TABLE 76 NORTH AMERICA: AI IN LIFE SCIENCE MARKET FOR NON-CLINICAL APPLICATIONS, BY TYPE, 2024–2031 (USD MILLION)
TABLE 77 NORTH AMERICA: AI IN LIFE SCIENCE MARKET, BY COMPONENT, 2024–2031 (USD MILLION)
TABLE 78 NORTH AMERICA: AI IN LIFE SCIENCE MARKET, BY TOOL, 2024–2031 (USD MILLION)
TABLE 79 NORTH AMERICA: AI IN LIFE SCIENCE MARKET FOR MACHINE LEARNING, BY TYPE, 2024–2031 (USD MILLION)
TABLE 80 NORTH AMERICA: AI IN LIFE SCIENCE MARKET FOR DEEP LEARNING, BY TYPE, 2024–2031 (USD MILLION)
TABLE 81 NORTH AMERICA: AI IN LIFE SCIENCE MARKET, BY DEPLOYMENT MODE, 2024–2031 (USD MILLION)
TABLE 82 NORTH AMERICA: AI IN LIFE SCIENCE MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 83 US: AI IN LIFE SCIENCE MARKET, BY OFFERING, 2024–2031 (USD MILLION)
TABLE 84 US: AI IN LIFE SCIENCE MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
TABLE 85 US: AI IN LIFE SCIENCE MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2024–2031 (USD MILLION)
TABLE 86 US: AI IN LIFE SCIENCE MARKET FOR NON-CLINICAL APPLICATIONS, BY TYPE, 2024–2031 (USD MILLION)
TABLE 87 US: AI IN LIFE SCIENCE MARKET, BY COMPONENT, 2024–2031 (USD MILLION)
TABLE 88 US: AI IN LIFE SCIENCE MARKET, BY TOOL, 2024–2031 (USD MILLION)
TABLE 89 US: AI IN LIFE SCIENCE MARKET FOR MACHINE LEARNING, BY TYPE, 2024–2031 (USD MILLION)
TABLE 90 US: AI IN LIFE SCIENCE MARKET FOR DEEP LEARNING, BY TYPE, 2024–2031 (USD MILLION)
TABLE 91 US: AI IN LIFE SCIENCE MARKET, BY DEPLOYMENT MODE, 2024–2031 (USD MILLION)
TABLE 92 US: AI IN LIFE SCIENCE MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 93 CANADA: AI IN LIFE SCIENCE MARKET, BY OFFERING, 2024–2031 (USD MILLION)
TABLE 94 CANADA: AI IN LIFE SCIENCE MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
TABLE 95 CANADA: AI IN LIFE SCIENCE MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2024–2031 (USD MILLION)
TABLE 96 CANADA: AI IN LIFE SCIENCE MARKET FOR NON-CLINICAL APPLICATIONS, BY TYPE, 2024–2031 (USD MILLION)
TABLE 97 CANADA: AI IN LIFE SCIENCE MARKET, BY COMPONENT, 2024–2031 (USD MILLION)
TABLE 98 CANADA: AI IN LIFE SCIENCE MARKET, BY TOOL, 2024–2031 (USD MILLION)
TABLE 99 CANADA: AI IN LIFE SCIENCE MARKET FOR MACHINE LEARNING, BY TYPE, 2024–2031 (USD MILLION)
TABLE 100 CANADA: AI IN LIFE SCIENCE MARKET FOR DEEP LEARNING, BY TYPE, 2024–2031 (USD MILLION)
TABLE 101 CANADA: AI IN LIFE SCIENCE MARKET, BY DEPLOYMENT MODE, 2024–2031 (USD MILLION)
TABLE 102 CANADA: AI IN LIFE SCIENCE MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 103 EUROPE: AI IN LIFE SCIENCE MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 104 EUROPE: AI IN LIFE SCIENCE MARKET, BY OFFERING, 2024–2031 (USD MILLION)
TABLE 105 EUROPE: AI IN LIFE SCIENCE MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
TABLE 106 EUROPE: AI IN LIFE SCIENCE MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2024–2031 (USD MILLION)
TABLE 107 EUROPE: AI IN LIFE SCIENCE MARKET FOR NON-CLINICAL APPLICATIONS, BY TYPE, 2024–2031 (USD MILLION)
TABLE 108 EUROPE: AI IN LIFE SCIENCE MARKET, BY COMPONENT, 2024–2031 (USD MILLION)
TABLE 109 EUROPE: AI IN LIFE SCIENCE MARKET, BY TOOL, 2024–2031 (USD MILLION)
TABLE 110 EUROPE: AI IN LIFE SCIENCE MARKET FOR MACHINE LEARNING, BY TYPE, 2024–2031 (USD MILLION)
TABLE 111 EUROPE: AI IN LIFE SCIENCE MARKET FOR DEEP LEARNING, BY TYPE, 2024–2031 (USD MILLION)
TABLE 112 EUROPE: AI IN LIFE SCIENCE MARKET, BY DEPLOYMENT MODE, 2024–2031 (USD MILLION)
TABLE 113 EUROPE: AI IN LIFE SCIENCE MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 114 GERMANY: AI IN LIFE SCIENCE MARKET, BY OFFERING, 2024–2031 (USD MILLION)
TABLE 115 GERMANY: AI IN LIFE SCIENCE MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
TABLE 116 GERMANY: AI IN LIFE SCIENCE MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2024–2031 (USD MILLION)
TABLE 117 GERMANY: AI IN LIFE SCIENCE MARKET FOR NON-CLINICAL APPLICATIONS, BY TYPE, 2024–2031 (USD MILLION)
TABLE 118 GERMANY: AI IN LIFE SCIENCE MARKET, BY COMPONENT, 2024–2031 (USD MILLION)
TABLE 119 GERMANY: AI IN LIFE SCIENCE MARKET, BY TOOL, 2024–2031 (USD MILLION)
TABLE 120 GERMANY: AI IN LIFE SCIENCE MARKET FOR MACHINE LEARNING, BY TYPE, 2024–2031 (USD MILLION)
TABLE 121 GERMANY: AI IN LIFE SCIENCE MARKET FOR DEEP LEARNING, BY TYPE, 2024–2031 (USD MILLION)
TABLE 122 GERMANY: AI IN LIFE SCIENCE MARKET, BY DEPLOYMENT MODE, 2024–2031 (USD MILLION)
TABLE 123 GERMANY: AI IN LIFE SCIENCE MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 124 FRANCE: AI IN LIFE SCIENCE MARKET, BY OFFERING, 2024–2031 (USD MILLION)
TABLE 125 FRANCE: AI IN LIFE SCIENCE MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
TABLE 126 FRANCE: AI IN LIFE SCIENCE MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2024–2031 (USD MILLION)
TABLE 127 FRANCE: AI IN LIFE SCIENCE MARKET FOR NON-CLINICAL APPLICATIONS, BY TYPE, 2024–2031 (USD MILLION)
TABLE 128 FRANCE: AI IN LIFE SCIENCE MARKET, BY COMPONENT, 2024–2031 (USD MILLION)
TABLE 129 FRANCE: AI IN LIFE SCIENCE MARKET, BY TOOL, 2024–2031 (USD MILLION)
TABLE 130 FRANCE: AI IN LIFE SCIENCE MARKET FOR MACHINE LEARNING, BY TYPE, 2024–2031 (USD MILLION)
TABLE 131 FRANCE: AI IN LIFE SCIENCE MARKET FOR DEEP LEARNING, BY TYPE, 2024–2031 (USD MILLION)
TABLE 132 FRANCE: AI IN LIFE SCIENCE MARKET, BY DEPLOYMENT MODE, 2024–2031 (USD MILLION)
TABLE 133 FRANCE: AI IN LIFE SCIENCE MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 134 UK: AI IN LIFE SCIENCE MARKET, BY OFFERING, 2024–2031 (USD MILLION)
TABLE 135 UK: AI IN LIFE SCIENCE MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
TABLE 136 UK: AI IN LIFE SCIENCE MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2024–2031 (USD MILLION)
TABLE 137 UK: AI IN LIFE SCIENCE MARKET FOR NON-CLINICAL APPLICATIONS, BY TYPE, 2024–2031 (USD MILLION)
TABLE 138 UK: AI IN LIFE SCIENCE MARKET, BY COMPONENT, 2024–2031 (USD MILLION)
TABLE 139 UK: AI IN LIFE SCIENCE MARKET, BY TOOL, 2024–2031 (USD MILLION)
TABLE 140 UK: AI IN LIFE SCIENCE MARKET FOR MACHINE LEARNING, BY TYPE, 2024–2031 (USD MILLION)
TABLE 141 UK: AI IN LIFE SCIENCE MARKET FOR DEEP LEARNING, BY TYPE, 2024–2031 (USD MILLION)
TABLE 142 UK: AI IN LIFE SCIENCE MARKET, BY DEPLOYMENT MODE, 2024–2031 (USD MILLION)
TABLE 143 UK: AI IN LIFE SCIENCE MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 144 ITALY: AI IN LIFE SCIENCE MARKET, BY OFFERING, 2024–2031 (USD MILLION)
TABLE 145 ITALY: AI IN LIFE SCIENCE MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
TABLE 146 ITALY: AI IN LIFE SCIENCE MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2024–2031 (USD MILLION)
TABLE 147 ITALY: AI IN LIFE SCIENCE MARKET FOR NON-CLINICAL APPLICATIONS, BY TYPE, 2024–2031 (USD MILLION)
TABLE 148 ITALY: AI IN LIFE SCIENCE MARKET, BY COMPONENT, 2024–2031 (USD MILLION)
TABLE 149 ITALY: AI IN LIFE SCIENCE MARKET, BY TOOL, 2024–2031 (USD MILLION)
TABLE 150 ITALY: AI IN LIFE SCIENCE MARKET FOR MACHINE LEARNING, BY TYPE, 2024–2031 (USD MILLION)
TABLE 151 ITALY: AI IN LIFE SCIENCE MARKET FOR DEEP LEARNING, BY TYPE, 2024–2031 (USD MILLION)
TABLE 152 ITALY: AI IN LIFE SCIENCE MARKET, BY DEPLOYMENT MODE, 2024–2031 (USD MILLION)
TABLE 153 ITALY: AI IN LIFE SCIENCE MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 154 SPAIN: AI IN LIFE SCIENCE MARKET, BY OFFERING, 2024–2031 (USD MILLION)
TABLE 155 SPAIN: AI IN LIFE SCIENCE MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
TABLE 156 SPAIN: AI IN LIFE SCIENCE MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2024–2031 (USD MILLION)
TABLE 157 SPAIN: AI IN LIFE SCIENCE MARKET FOR NON-CLINICAL APPLICATIONS, BY TYPE, 2024–2031 (USD MILLION)
TABLE 158 SPAIN: AI IN LIFE SCIENCE MARKET, BY COMPONENT, 2024–2031 (USD MILLION)
TABLE 159 SPAIN: AI IN LIFE SCIENCE MARKET, BY TOOL, 2024–2031 (USD MILLION)
TABLE 160 SPAIN: AI IN LIFE SCIENCE MARKET FOR MACHINE LEARNING, BY TYPE, 2024–2031 (USD MILLION)
TABLE 161 SPAIN: AI IN LIFE SCIENCE MARKET FOR DEEP LEARNING, BY TYPE, 2024–2031 (USD MILLION)
TABLE 162 SPAIN: AI IN LIFE SCIENCE MARKET, BY DEPLOYMENT MODE, 2024–2031 (USD MILLION)
TABLE 163 SPAIN: AI IN LIFE SCIENCE MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 164 REST OF EUROPE: AI IN LIFE SCIENCE MARKET, BY OFFERING, 2024–2031 (USD MILLION)
TABLE 165 REST OF EUROPE: AI IN LIFE SCIENCE MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
TABLE 166 REST OF EUROPE: AI IN LIFE SCIENCE MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2024–2031 (USD MILLION)
TABLE 167 REST OF EUROPE: AI IN LIFE SCIENCE MARKET FOR NON-CLINICAL APPLICATIONS, BY TYPE, 2024–2031 (USD MILLION)
TABLE 168 REST OF EUROPE: AI IN LIFE SCIENCE MARKET, BY COMPONENT, 2024–2031 (USD MILLION)
TABLE 169 REST OF EUROPE: AI IN LIFE SCIENCE MARKET, BY TOOL, 2024–2031 (USD MILLION)
TABLE 170 REST OF EUROPE: AI IN LIFE SCIENCE MARKET FOR MACHINE LEARNING, BY TYPE, 2024–2031 (USD MILLION)
TABLE 171 REST OF EUROPE: AI IN LIFE SCIENCE MARKET FOR DEEP LEARNING, BY TYPE, 2024–2031 (USD MILLION)
TABLE 172 REST OF EUROPE: AI IN LIFE SCIENCE MARKET, BY DEPLOYMENT MODE, 2024–2031 (USD MILLION)
TABLE 173 REST OF EUROPE: AI IN LIFE SCIENCE MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 174 ASIA PACIFIC: AI IN LIFE SCIENCE MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 175 ASIA PACIFIC: AI IN LIFE SCIENCE MARKET, BY OFFERING, 2024–2031 (USD MILLION)
TABLE 176 ASIA PACIFIC: AI IN LIFE SCIENCE MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
TABLE 177 ASIA PACIFIC: AI IN LIFE SCIENCE MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2024–2031 (USD MILLION)
TABLE 178 ASIA PACIFIC: AI IN LIFE SCIENCE MARKET FOR NON-CLINICAL APPLICATIONS, BY TYPE, 2024–2031 (USD MILLION)
TABLE 179 ASIA PACIFIC: AI IN LIFE SCIENCE MARKET, BY COMPONENT, 2024–2031 (USD MILLION)
TABLE 180 ASIA PACIFIC: AI IN LIFE SCIENCE MARKET, BY TOOL, 2024–2031 (USD MILLION)
TABLE 181 ASIA PACIFIC: AI IN LIFE SCIENCE MARKET FOR MACHINE LEARNING, BY TYPE, 2024–2031 (USD MILLION)
TABLE 182 ASIA PACIFIC: AI IN LIFE SCIENCE MARKET FOR DEEP LEARNING, BY TYPE, 2024–2031 (USD MILLION)
TABLE 183 ASIA PACIFIC: AI IN LIFE SCIENCE MARKET, BY DEPLOYMENT MODE, 2024–2031 (USD MILLION)
TABLE 184 ASIA PACIFIC: AI IN LIFE SCIENCE MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 185 CHINA: AI IN LIFE SCIENCE MARKET, BY OFFERING, 2024–2031 (USD MILLION)
TABLE 186 CHINA: AI IN LIFE SCIENCE MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
TABLE 187 CHINA: AI IN LIFE SCIENCE MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2024–2031 (USD MILLION)
TABLE 188 CHINA: AI IN LIFE SCIENCE MARKET FOR NON-CLINICAL APPLICATIONS, BY TYPE, 2024–2031 (USD MILLION)
TABLE 189 CHINA: AI IN LIFE SCIENCE MARKET, BY COMPONENT, 2024–2031 (USD MILLION)
TABLE 190 CHINA: AI IN LIFE SCIENCE MARKET, BY TOOL, 2024–2031 (USD MILLION)
TABLE 191 CHINA: AI IN LIFE SCIENCE MARKET FOR MACHINE LEARNING, BY TYPE, 2024–2031 (USD MILLION)
TABLE 192 CHINA: AI IN LIFE SCIENCE MARKET FOR DEEP LEARNING, BY TYPE, 2024–2031 (USD MILLION)
TABLE 193 CHINA: AI IN LIFE SCIENCE MARKET, BY DEPLOYMENT MODE, 2024–2031 (USD MILLION)
TABLE 194 CHINA: AI IN LIFE SCIENCE MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 195 JAPAN: AI IN LIFE SCIENCE MARKET, BY OFFERING, 2024–2031 (USD MILLION)
TABLE 196 JAPAN: AI IN LIFE SCIENCE MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
TABLE 197 JAPAN: AI IN LIFE SCIENCE MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2024–2031 (USD MILLION)
TABLE 198 JAPAN: AI IN LIFE SCIENCE MARKET FOR NON-CLINICAL APPLICATIONS, BY TYPE, 2024–2031 (USD MILLION)
TABLE 199 JAPAN: AI IN LIFE SCIENCE MARKET, BY COMPONENT, 2024–2031 (USD MILLION)
TABLE 200 JAPAN: AI IN LIFE SCIENCE MARKET, BY TOOL, 2024–2031 (USD MILLION)
TABLE 201 JAPAN: AI IN LIFE SCIENCE MARKET FOR MACHINE LEARNING, BY TYPE, 2024–2031 (USD MILLION)
TABLE 202 JAPAN: AI IN LIFE SCIENCE MARKET FOR DEEP LEARNING, BY TYPE, 2024–2031 (USD MILLION)
TABLE 203 JAPAN: AI IN LIFE SCIENCE MARKET, BY DEPLOYMENT MODE, 2024–2031 (USD MILLION)
TABLE 204 JAPAN: AI IN LIFE SCIENCE MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 205 INDIA: AI IN LIFE SCIENCE MARKET, BY OFFERING, 2024–2031 (USD MILLION)
TABLE 206 INDIA: AI IN LIFE SCIENCE MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
TABLE 207 INDIA: AI IN LIFE SCIENCE MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2024–2031 (USD MILLION)
TABLE 208 INDIA: AI IN LIFE SCIENCE MARKET FOR NON-CLINICAL APPLICATIONS, BY TYPE, 2024–2031 (USD MILLION)
TABLE 209 INDIA: AI IN LIFE SCIENCE MARKET, BY COMPONENT, 2024–2031 (USD MILLION)
TABLE 210 INDIA: AI IN LIFE SCIENCE MARKET, BY TOOL, 2024–2031 (USD MILLION)
TABLE 211 INDIA: AI IN LIFE SCIENCE MARKET FOR MACHINE LEARNING, BY TYPE, 2024–2031 (USD MILLION)
TABLE 212 INDIA: AI IN LIFE SCIENCE MARKET FOR DEEP LEARNING, BY TYPE, 2024–2031 (USD MILLION)
TABLE 213 INDIA: AI IN LIFE SCIENCE MARKET, BY DEPLOYMENT MODE, 2024–2031 (USD MILLION)
TABLE 214 INDIA: AI IN LIFE SCIENCE MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 1 EXCHANGE RATES UTILIZED FOR CONVERSION TO USD
TABLE 2 AI IN LIFE SCIENCE MARKET: PORTER’S FIVE FORCES ANALYSIS
TABLE 3 AI IN LIFE SCIENCE MARKET: ROLE IN ECOSYSTEM
TABLE 4 CASE 1: GENERATIVE AI ACCELERATES DRUG DISCOVERY, CLINICAL RESEARCH, AND OPERATIONAL EFFICIENCY IN LIFE SCIENCES
TABLE 5 CASE 2: JOHNSON & JOHNSON EXPANDS AI INTEGRATION ACROSS DRUG DISCOVERY, SURGICAL INNOVATION, AND HEALTHCARE OPERATIONS
TABLE 6 CASE 3: AI-DRIVEN DRUG DISCOVERY AND CLINICAL OPTIMIZATION ACCELERATE INNOVATION IN LIFE SCIENCES
TABLE 7 US ADJUSTED RECIPROCAL TARIFF RATES
TABLE 8 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 9 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 10 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 11 LATIN AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 12 MIDDLE EAST & AFRICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 13 JURISDICTION ANALYSIS OF TOP APPLICANT COUNTRIES FOR AI IN LIFE SCIENCE MARKET
TABLE 14 AI IN LIFE SCIENCE MARKET: KEY PATENTS/PATENT APPLICATIONS
TABLE 15 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF TOP THREE END USERS (%)
TABLE 16 KEY BUYING CRITERIA FOR TOP THREE END USERS
TABLE 17 UNMET NEEDS IN AI IN LIFE SCIENCE MARKET
TABLE 18 END USER EXPECTATIONS IN AI IN LIFE SCIENCE MARKET
TABLE 19 AI IN LIFE SCIENCE MARKET, BY TOOL, 2024–2031 (USD MILLION)
TABLE 20 AI IN LIFE SCIENCE MARKET FOR MACHINE LEARNING, BY TYPE, 2024–2031 (USD MILLION)
TABLE 21 AI IN LIFE SCIENCE MARKET FOR MACHINE LEARNING, BY REGION, 2024–2031 (USD MILLION)
TABLE 22 AI IN LIFE SCIENCE MARKET FOR DEEP LEARNING, BY TYPE, 2024–2031 (USD MILLION)
TABLE 23 AI IN LIFE SCIENCE MARKET FOR DEEP LEARNING, BY REGION, 2024–2031 (USD MILLION)
TABLE 24 AI IN LIFE SCIENCE MARKET FOR CONVOLUTIONAL NEURAL NETWORKS, BY REGION, 2024–2031 (USD MILLION)
TABLE 25 AI IN LIFE SCIENCE MARKET FOR RECURRENT NEURAL NETWORKS, BY REGION, 2024–2031 (USD MILLION)
TABLE 26 AI IN LIFE SCIENCE MARKET FOR GENERATIVE ADVERSARIAL NETWORKS, BY REGION, 2024–2031 (USD MILLION)
TABLE 27 AI IN LIFE SCIENCE MARKET FOR GRAPH NEURAL NETWORKS, BY REGION, 2024–2031 (USD MILLION)
TABLE 28 AI IN LIFE SCIENCE MARKET FOR OTHER DEEP LEARNING TOOLS, BY REGION, 2024–2031 (USD MILLION)
TABLE 29 AI IN LIFE SCIENCE MARKET FOR SUPERVISED LEARNING, BY REGION, 2024–2031 (USD MILLION)
TABLE 30 AI IN LIFE SCIENCE MARKET FOR REINFORCEMENT LEARNING, BY REGION, 2024–2031 (USD MILLION)
TABLE 31 AI IN LIFE SCIENCE MARKET FOR UNSUPERVISED LEARNING, BY REGION, 2024–2031 (USD MILLION)
TABLE 32 AI IN LIFE SCIENCE MARKET FOR OTHER MACHINE LEARNING TECHNOLOGIES, BY REGION, 2024–2031 (USD MILLION)
TABLE 33 AI IN LIFE SCIENCE MARKET FOR NATURAL LANGUAGE PROCESSING, BY REGION, 2024–2031 (USD MILLION)
TABLE 34 AI IN LIFE SCIENCE MARKET FOR CONTEXT-AWARE PROCESSING AND COMPUTING, BY REGION, 2024–2031 (USD MILLION)
TABLE 35 AI IN LIFE SCIENCE MARKET FOR COMPUTER VISION, BY REGION, 2024–2031 (USD MILLION)
TABLE 36 AI IN LIFE SCIENCE MARKET FOR IMAGE ANALYSIS, BY REGION, 2024–2031 (USD MILLION)
TABLE 37 AI IN LIFE SCIENCE MARKET FOR OTHER TOOLS, BY REGION, 2024–2031 (USD MILLION)
TABLE 38 AI IN LIFE SCIENCE MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
TABLE 39 AI IN LIFE SCIENCE MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2024–2031 (USD MILLION)
TABLE 40 AI IN LIFE SCIENCE MARKET FOR CLINICAL APPLICATIONS, BY REGION, 2024–2031 (USD MILLION)
TABLE 41 AI IN LIFE SCIENCE MARKET FOR DRUG DISCOVERY, BY REGION, 2024–2031 (USD MILLION)
TABLE 42 AI IN LIFE SCIENCE MARKET FOR MEDICAL IMAGING AND DIAGNOSTICS, BY REGION, 2024–2031 (USD MILLION)
TABLE 43 AI IN LIFE SCIENCE MARKET FOR CLINICAL TRIALS, BY REGION, 2024–2031 (USD MILLION)
TABLE 44 AI IN LIFE SCIENCE MARKET FOR PRECISION MEDICINE, BY REGION, 2024–2031 (USD MILLION)
TABLE 45 AI IN LIFE SCIENCE MARKET FOR OTHER CLINICAL APPLICATIONS, BY REGION, 2024–2031 (USD MILLION)
TABLE 46 AI IN LIFE SCIENCE MARKET FOR NON-CLINICAL APPLICATIONS, BY TYPE, 2024–2031 (USD MILLION)
TABLE 47 AI IN LIFE SCIENCE MARKET FOR NON-CLINICAL APPLICATIONS, BY REGION, 2024–2031 (USD MILLION)
TABLE 48 AI IN LIFE SCIENCE MARKET FOR R&D SUPPORT, BY REGION, 2024–2031 (USD MILLION)
TABLE 49 AI IN LIFE SCIENCE MARKET FOR DATA ANALYTICS AND REPORTING, BY REGION, 2024–2031 (USD MILLION)
TABLE 50 AI IN LIFE SCIENCE MARKET FOR MANUFACTURING & QUALITY ASSURANCE, BY REGION, 2024–2031 (USD MILLION)
TABLE 51 AI IN LIFE SCIENCE MARKET FOR REGULATORY AFFAIRS, BY REGION, 2024–2031 (USD MILLION)
TABLE 52 AI IN LIFE SCIENCE MARKET, BY COMPONENT, 2024–2031 (USD MILLION)
TABLE 53 AI IN LIFE SCIENCE MARKET FOR SOFTWARE, BY REGION, 2024–2031 (USD MILLION)
TABLE 54 AI IN LIFE SCIENCE MARKET FOR SERVICE, BY REGION, 2024–2031 (USD MILLION)
TABLE 55 AI IN LIFE SCIENCE MARKET, BY DEPLOYMENT, 2024–2031 (USD MILLION)
TABLE 56 AI IN LIFE SCIENCE MARKET FOR CLOUD-BASED SOLUTIONS, BY REGION, 2024–2031 (USD MILLION)
TABLE 57 AI IN LIFE SCIENCE MARKET FOR ON-PREMISE SOLUTIONS, BY REGION, 2024–2031 (USD MILLION)
TABLE 58 AI IN LIFE SCIENCE MARKET FOR HYBRID SOLUTIONS, BY REGION, 2024–2031 (USD MILLION)
TABLE 59 AI IN LIFE SCIENCE MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 60 AI IN LIFE SCIENCE MARKET FOR CRO & CDMO, BY REGION, 2024–2031 (USD MILLION)
TABLE 61 AI IN LIFE SCIENCE MARKET FOR PHARMACEUTICAL COMPANIES, BY REGION, 2024–2031 (USD MILLION)
TABLE 62 AI IN LIFE SCIENCE MARKET FOR BIOTECHNOLOGY COMPANIES, BY REGION, 2024–2031 (USD MILLION)
TABLE 63 AI IN LIFE SCIENCE MARKET FOR DIAGNOSTIC COMPANIES, BY REGION, 2024–2031 (USD MILLION)
TABLE 64 AI IN LIFE SCIENCE MARKET FOR ACADEMIC AND GOVERNMENT LABORATORIES, BY REGION, 2024–2031 (USD MILLION)
TABLE 65 AI IN LIFE SCIENCE MARKET FOR OTHER END USERS, BY REGION, 2024–2031 (USD MILLION)
TABLE 66 AI IN LIFE SCIENCE MARKET, BY OFFERING, 2024–2031 (USD MILLION)
TABLE 67 AI IN LIFE SCIENCE MARKET FOR END-TO-END SOLUTIONS, BY REGION, 2024–2031 (USD MILLION)
TABLE 68 AI IN LIFE SCIENCE MARKET FOR NICHE/POINT SOLUTIONS, BY REGION, 2024–2031 (USD MILLION)
TABLE 69 AI IN LIFE SCIENCE MARKET FOR AI TECHNOLOGY, BY REGION, 2024–2031 (USD MILLION)
TABLE 70 AI IN LIFE SCIENCE MARKET FOR SERVICES, BY REGION, 2024–2031 (USD MILLION)
TABLE 71 AI IN LIFE SCIENCE MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 72 NORTH AMERICA: AI IN LIFE SCIENCE MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 73 NORTH AMERICA: AI IN LIFE SCIENCE MARKET, BY OFFERING, 2024–2031 (USD MILLION)
TABLE 74 NORTH AMERICA: AI IN LIFE SCIENCE MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
TABLE 75 NORTH AMERICA: AI IN LIFE SCIENCE MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2024–2031 (USD MILLION)
TABLE 76 NORTH AMERICA: AI IN LIFE SCIENCE MARKET FOR NON-CLINICAL APPLICATIONS, BY TYPE, 2024–2031 (USD MILLION)
TABLE 77 NORTH AMERICA: AI IN LIFE SCIENCE MARKET, BY COMPONENT, 2024–2031 (USD MILLION)
TABLE 78 NORTH AMERICA: AI IN LIFE SCIENCE MARKET, BY TOOL, 2024–2031 (USD MILLION)
TABLE 79 NORTH AMERICA: AI IN LIFE SCIENCE MARKET FOR MACHINE LEARNING, BY TYPE, 2024–2031 (USD MILLION)
TABLE 80 NORTH AMERICA: AI IN LIFE SCIENCE MARKET FOR DEEP LEARNING, BY TYPE, 2024–2031 (USD MILLION)
TABLE 81 NORTH AMERICA: AI IN LIFE SCIENCE MARKET, BY DEPLOYMENT MODE, 2024–2031 (USD MILLION)
TABLE 82 NORTH AMERICA: AI IN LIFE SCIENCE MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 83 US: AI IN LIFE SCIENCE MARKET, BY OFFERING, 2024–2031 (USD MILLION)
TABLE 84 US: AI IN LIFE SCIENCE MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
TABLE 85 US: AI IN LIFE SCIENCE MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2024–2031 (USD MILLION)
TABLE 86 US: AI IN LIFE SCIENCE MARKET FOR NON-CLINICAL APPLICATIONS, BY TYPE, 2024–2031 (USD MILLION)
TABLE 87 US: AI IN LIFE SCIENCE MARKET, BY COMPONENT, 2024–2031 (USD MILLION)
TABLE 88 US: AI IN LIFE SCIENCE MARKET, BY TOOL, 2024–2031 (USD MILLION)
TABLE 89 US: AI IN LIFE SCIENCE MARKET FOR MACHINE LEARNING, BY TYPE, 2024–2031 (USD MILLION)
TABLE 90 US: AI IN LIFE SCIENCE MARKET FOR DEEP LEARNING, BY TYPE, 2024–2031 (USD MILLION)
TABLE 91 US: AI IN LIFE SCIENCE MARKET, BY DEPLOYMENT MODE, 2024–2031 (USD MILLION)
TABLE 92 US: AI IN LIFE SCIENCE MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 93 CANADA: AI IN LIFE SCIENCE MARKET, BY OFFERING, 2024–2031 (USD MILLION)
TABLE 94 CANADA: AI IN LIFE SCIENCE MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
TABLE 95 CANADA: AI IN LIFE SCIENCE MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2024–2031 (USD MILLION)
TABLE 96 CANADA: AI IN LIFE SCIENCE MARKET FOR NON-CLINICAL APPLICATIONS, BY TYPE, 2024–2031 (USD MILLION)
TABLE 97 CANADA: AI IN LIFE SCIENCE MARKET, BY COMPONENT, 2024–2031 (USD MILLION)
TABLE 98 CANADA: AI IN LIFE SCIENCE MARKET, BY TOOL, 2024–2031 (USD MILLION)
TABLE 99 CANADA: AI IN LIFE SCIENCE MARKET FOR MACHINE LEARNING, BY TYPE, 2024–2031 (USD MILLION)
TABLE 100 CANADA: AI IN LIFE SCIENCE MARKET FOR DEEP LEARNING, BY TYPE, 2024–2031 (USD MILLION)
TABLE 101 CANADA: AI IN LIFE SCIENCE MARKET, BY DEPLOYMENT MODE, 2024–2031 (USD MILLION)
TABLE 102 CANADA: AI IN LIFE SCIENCE MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 103 EUROPE: AI IN LIFE SCIENCE MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 104 EUROPE: AI IN LIFE SCIENCE MARKET, BY OFFERING, 2024–2031 (USD MILLION)
TABLE 105 EUROPE: AI IN LIFE SCIENCE MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
TABLE 106 EUROPE: AI IN LIFE SCIENCE MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2024–2031 (USD MILLION)
TABLE 107 EUROPE: AI IN LIFE SCIENCE MARKET FOR NON-CLINICAL APPLICATIONS, BY TYPE, 2024–2031 (USD MILLION)
TABLE 108 EUROPE: AI IN LIFE SCIENCE MARKET, BY COMPONENT, 2024–2031 (USD MILLION)
TABLE 109 EUROPE: AI IN LIFE SCIENCE MARKET, BY TOOL, 2024–2031 (USD MILLION)
TABLE 110 EUROPE: AI IN LIFE SCIENCE MARKET FOR MACHINE LEARNING, BY TYPE, 2024–2031 (USD MILLION)
TABLE 111 EUROPE: AI IN LIFE SCIENCE MARKET FOR DEEP LEARNING, BY TYPE, 2024–2031 (USD MILLION)
TABLE 112 EUROPE: AI IN LIFE SCIENCE MARKET, BY DEPLOYMENT MODE, 2024–2031 (USD MILLION)
TABLE 113 EUROPE: AI IN LIFE SCIENCE MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 114 GERMANY: AI IN LIFE SCIENCE MARKET, BY OFFERING, 2024–2031 (USD MILLION)
TABLE 115 GERMANY: AI IN LIFE SCIENCE MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
TABLE 116 GERMANY: AI IN LIFE SCIENCE MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2024–2031 (USD MILLION)
TABLE 117 GERMANY: AI IN LIFE SCIENCE MARKET FOR NON-CLINICAL APPLICATIONS, BY TYPE, 2024–2031 (USD MILLION)
TABLE 118 GERMANY: AI IN LIFE SCIENCE MARKET, BY COMPONENT, 2024–2031 (USD MILLION)
TABLE 119 GERMANY: AI IN LIFE SCIENCE MARKET, BY TOOL, 2024–2031 (USD MILLION)
TABLE 120 GERMANY: AI IN LIFE SCIENCE MARKET FOR MACHINE LEARNING, BY TYPE, 2024–2031 (USD MILLION)
TABLE 121 GERMANY: AI IN LIFE SCIENCE MARKET FOR DEEP LEARNING, BY TYPE, 2024–2031 (USD MILLION)
TABLE 122 GERMANY: AI IN LIFE SCIENCE MARKET, BY DEPLOYMENT MODE, 2024–2031 (USD MILLION)
TABLE 123 GERMANY: AI IN LIFE SCIENCE MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 124 FRANCE: AI IN LIFE SCIENCE MARKET, BY OFFERING, 2024–2031 (USD MILLION)
TABLE 125 FRANCE: AI IN LIFE SCIENCE MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
TABLE 126 FRANCE: AI IN LIFE SCIENCE MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2024–2031 (USD MILLION)
TABLE 127 FRANCE: AI IN LIFE SCIENCE MARKET FOR NON-CLINICAL APPLICATIONS, BY TYPE, 2024–2031 (USD MILLION)
TABLE 128 FRANCE: AI IN LIFE SCIENCE MARKET, BY COMPONENT, 2024–2031 (USD MILLION)
TABLE 129 FRANCE: AI IN LIFE SCIENCE MARKET, BY TOOL, 2024–2031 (USD MILLION)
TABLE 130 FRANCE: AI IN LIFE SCIENCE MARKET FOR MACHINE LEARNING, BY TYPE, 2024–2031 (USD MILLION)
TABLE 131 FRANCE: AI IN LIFE SCIENCE MARKET FOR DEEP LEARNING, BY TYPE, 2024–2031 (USD MILLION)
TABLE 132 FRANCE: AI IN LIFE SCIENCE MARKET, BY DEPLOYMENT MODE, 2024–2031 (USD MILLION)
TABLE 133 FRANCE: AI IN LIFE SCIENCE MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 134 UK: AI IN LIFE SCIENCE MARKET, BY OFFERING, 2024–2031 (USD MILLION)
TABLE 135 UK: AI IN LIFE SCIENCE MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
TABLE 136 UK: AI IN LIFE SCIENCE MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2024–2031 (USD MILLION)
TABLE 137 UK: AI IN LIFE SCIENCE MARKET FOR NON-CLINICAL APPLICATIONS, BY TYPE, 2024–2031 (USD MILLION)
TABLE 138 UK: AI IN LIFE SCIENCE MARKET, BY COMPONENT, 2024–2031 (USD MILLION)
TABLE 139 UK: AI IN LIFE SCIENCE MARKET, BY TOOL, 2024–2031 (USD MILLION)
TABLE 140 UK: AI IN LIFE SCIENCE MARKET FOR MACHINE LEARNING, BY TYPE, 2024–2031 (USD MILLION)
TABLE 141 UK: AI IN LIFE SCIENCE MARKET FOR DEEP LEARNING, BY TYPE, 2024–2031 (USD MILLION)
TABLE 142 UK: AI IN LIFE SCIENCE MARKET, BY DEPLOYMENT MODE, 2024–2031 (USD MILLION)
TABLE 143 UK: AI IN LIFE SCIENCE MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 144 ITALY: AI IN LIFE SCIENCE MARKET, BY OFFERING, 2024–2031 (USD MILLION)
TABLE 145 ITALY: AI IN LIFE SCIENCE MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
TABLE 146 ITALY: AI IN LIFE SCIENCE MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2024–2031 (USD MILLION)
TABLE 147 ITALY: AI IN LIFE SCIENCE MARKET FOR NON-CLINICAL APPLICATIONS, BY TYPE, 2024–2031 (USD MILLION)
TABLE 148 ITALY: AI IN LIFE SCIENCE MARKET, BY COMPONENT, 2024–2031 (USD MILLION)
TABLE 149 ITALY: AI IN LIFE SCIENCE MARKET, BY TOOL, 2024–2031 (USD MILLION)
TABLE 150 ITALY: AI IN LIFE SCIENCE MARKET FOR MACHINE LEARNING, BY TYPE, 2024–2031 (USD MILLION)
TABLE 151 ITALY: AI IN LIFE SCIENCE MARKET FOR DEEP LEARNING, BY TYPE, 2024–2031 (USD MILLION)
TABLE 152 ITALY: AI IN LIFE SCIENCE MARKET, BY DEPLOYMENT MODE, 2024–2031 (USD MILLION)
TABLE 153 ITALY: AI IN LIFE SCIENCE MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 154 SPAIN: AI IN LIFE SCIENCE MARKET, BY OFFERING, 2024–2031 (USD MILLION)
TABLE 155 SPAIN: AI IN LIFE SCIENCE MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
TABLE 156 SPAIN: AI IN LIFE SCIENCE MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2024–2031 (USD MILLION)
TABLE 157 SPAIN: AI IN LIFE SCIENCE MARKET FOR NON-CLINICAL APPLICATIONS, BY TYPE, 2024–2031 (USD MILLION)
TABLE 158 SPAIN: AI IN LIFE SCIENCE MARKET, BY COMPONENT, 2024–2031 (USD MILLION)
TABLE 159 SPAIN: AI IN LIFE SCIENCE MARKET, BY TOOL, 2024–2031 (USD MILLION)
TABLE 160 SPAIN: AI IN LIFE SCIENCE MARKET FOR MACHINE LEARNING, BY TYPE, 2024–2031 (USD MILLION)
TABLE 161 SPAIN: AI IN LIFE SCIENCE MARKET FOR DEEP LEARNING, BY TYPE, 2024–2031 (USD MILLION)
TABLE 162 SPAIN: AI IN LIFE SCIENCE MARKET, BY DEPLOYMENT MODE, 2024–2031 (USD MILLION)
TABLE 163 SPAIN: AI IN LIFE SCIENCE MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 164 REST OF EUROPE: AI IN LIFE SCIENCE MARKET, BY OFFERING, 2024–2031 (USD MILLION)
TABLE 165 REST OF EUROPE: AI IN LIFE SCIENCE MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
TABLE 166 REST OF EUROPE: AI IN LIFE SCIENCE MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2024–2031 (USD MILLION)
TABLE 167 REST OF EUROPE: AI IN LIFE SCIENCE MARKET FOR NON-CLINICAL APPLICATIONS, BY TYPE, 2024–2031 (USD MILLION)
TABLE 168 REST OF EUROPE: AI IN LIFE SCIENCE MARKET, BY COMPONENT, 2024–2031 (USD MILLION)
TABLE 169 REST OF EUROPE: AI IN LIFE SCIENCE MARKET, BY TOOL, 2024–2031 (USD MILLION)
TABLE 170 REST OF EUROPE: AI IN LIFE SCIENCE MARKET FOR MACHINE LEARNING, BY TYPE, 2024–2031 (USD MILLION)
TABLE 171 REST OF EUROPE: AI IN LIFE SCIENCE MARKET FOR DEEP LEARNING, BY TYPE, 2024–2031 (USD MILLION)
TABLE 172 REST OF EUROPE: AI IN LIFE SCIENCE MARKET, BY DEPLOYMENT MODE, 2024–2031 (USD MILLION)
TABLE 173 REST OF EUROPE: AI IN LIFE SCIENCE MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 174 ASIA PACIFIC: AI IN LIFE SCIENCE MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 175 ASIA PACIFIC: AI IN LIFE SCIENCE MARKET, BY OFFERING, 2024–2031 (USD MILLION)
TABLE 176 ASIA PACIFIC: AI IN LIFE SCIENCE MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
TABLE 177 ASIA PACIFIC: AI IN LIFE SCIENCE MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2024–2031 (USD MILLION)
TABLE 178 ASIA PACIFIC: AI IN LIFE SCIENCE MARKET FOR NON-CLINICAL APPLICATIONS, BY TYPE, 2024–2031 (USD MILLION)
TABLE 179 ASIA PACIFIC: AI IN LIFE SCIENCE MARKET, BY COMPONENT, 2024–2031 (USD MILLION)
TABLE 180 ASIA PACIFIC: AI IN LIFE SCIENCE MARKET, BY TOOL, 2024–2031 (USD MILLION)
TABLE 181 ASIA PACIFIC: AI IN LIFE SCIENCE MARKET FOR MACHINE LEARNING, BY TYPE, 2024–2031 (USD MILLION)
TABLE 182 ASIA PACIFIC: AI IN LIFE SCIENCE MARKET FOR DEEP LEARNING, BY TYPE, 2024–2031 (USD MILLION)
TABLE 183 ASIA PACIFIC: AI IN LIFE SCIENCE MARKET, BY DEPLOYMENT MODE, 2024–2031 (USD MILLION)
TABLE 184 ASIA PACIFIC: AI IN LIFE SCIENCE MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 185 CHINA: AI IN LIFE SCIENCE MARKET, BY OFFERING, 2024–2031 (USD MILLION)
TABLE 186 CHINA: AI IN LIFE SCIENCE MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
TABLE 187 CHINA: AI IN LIFE SCIENCE MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2024–2031 (USD MILLION)
TABLE 188 CHINA: AI IN LIFE SCIENCE MARKET FOR NON-CLINICAL APPLICATIONS, BY TYPE, 2024–2031 (USD MILLION)
TABLE 189 CHINA: AI IN LIFE SCIENCE MARKET, BY COMPONENT, 2024–2031 (USD MILLION)
TABLE 190 CHINA: AI IN LIFE SCIENCE MARKET, BY TOOL, 2024–2031 (USD MILLION)
TABLE 191 CHINA: AI IN LIFE SCIENCE MARKET FOR MACHINE LEARNING, BY TYPE, 2024–2031 (USD MILLION)
TABLE 192 CHINA: AI IN LIFE SCIENCE MARKET FOR DEEP LEARNING, BY TYPE, 2024–2031 (USD MILLION)
TABLE 193 CHINA: AI IN LIFE SCIENCE MARKET, BY DEPLOYMENT MODE, 2024–2031 (USD MILLION)
TABLE 194 CHINA: AI IN LIFE SCIENCE MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 195 JAPAN: AI IN LIFE SCIENCE MARKET, BY OFFERING, 2024–2031 (USD MILLION)
TABLE 196 JAPAN: AI IN LIFE SCIENCE MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
TABLE 197 JAPAN: AI IN LIFE SCIENCE MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2024–2031 (USD MILLION)
TABLE 198 JAPAN: AI IN LIFE SCIENCE MARKET FOR NON-CLINICAL APPLICATIONS, BY TYPE, 2024–2031 (USD MILLION)
TABLE 199 JAPAN: AI IN LIFE SCIENCE MARKET, BY COMPONENT, 2024–2031 (USD MILLION)
TABLE 200 JAPAN: AI IN LIFE SCIENCE MARKET, BY TOOL, 2024–2031 (USD MILLION)
TABLE 201 JAPAN: AI IN LIFE SCIENCE MARKET FOR MACHINE LEARNING, BY TYPE, 2024–2031 (USD MILLION)
TABLE 202 JAPAN: AI IN LIFE SCIENCE MARKET FOR DEEP LEARNING, BY TYPE, 2024–2031 (USD MILLION)
TABLE 203 JAPAN: AI IN LIFE SCIENCE MARKET, BY DEPLOYMENT MODE, 2024–2031 (USD MILLION)
TABLE 204 JAPAN: AI IN LIFE SCIENCE MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 205 INDIA: AI IN LIFE SCIENCE MARKET, BY OFFERING, 2024–2031 (USD MILLION)
TABLE 206 INDIA: AI IN LIFE SCIENCE MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
TABLE 207 INDIA: AI IN LIFE SCIENCE MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2024–2031 (USD MILLION)
TABLE 208 INDIA: AI IN LIFE SCIENCE MARKET FOR NON-CLINICAL APPLICATIONS, BY TYPE, 2024–2031 (USD MILLION)
TABLE 209 INDIA: AI IN LIFE SCIENCE MARKET, BY COMPONENT, 2024–2031 (USD MILLION)
TABLE 210 INDIA: AI IN LIFE SCIENCE MARKET, BY TOOL, 2024–2031 (USD MILLION)
TABLE 211 INDIA: AI IN LIFE SCIENCE MARKET FOR MACHINE LEARNING, BY TYPE, 2024–2031 (USD MILLION)
TABLE 212 INDIA: AI IN LIFE SCIENCE MARKET FOR DEEP LEARNING, BY TYPE, 2024–2031 (USD MILLION)
TABLE 213 INDIA: AI IN LIFE SCIENCE MARKET, BY DEPLOYMENT MODE, 2024–2031 (USD MILLION)
TABLE 214 INDIA: AI IN LIFE SCIENCE MARKET, BY END USER, 2024–2031 (USD MILLION)
LIST OF FIGURES
FIGURE 1 MARKET SCENARIO
FIGURE 2 GLOBAL AI IN LIFE SCIENCE MARKET, 2024–2031
FIGURE 3 MAJOR STRATEGIES ADOPTED BY KEY PLAYERS IN AI IN LIFE SCIENCE MARKET, 2023–2026
FIGURE 4 DISRUPTIONS INFLUENCING GROWTH OF AI IN LIFE SCIENCE MARKET
FIGURE 5 HIGH-GROWTH SEGMENTS IN AI IN LIFE SCIENCE MARKET, 2026–2031
FIGURE 6 ASIA PACIFIC TO REGISTER HIGHEST CAGR IN AI IN LIFE SCIENCE MARKET DURING FORECAST PERIOD
FIGURE 7 GROWING ADOPTION OF PRECISION MEDICINE AND AI IN DRUG DISCOVERY TO DRIVE MARKET
FIGURE 8 CLINICAL APPLICATIONS IN NORTH AMERICA ACCOUNTED FOR LARGEST MARKET SHARE IN 2025
FIGURE 9 JAPAN TO REGISTER HIGHEST GROWTH RATE DURING FORECAST PERIOD
FIGURE 10 AI IN LIFE SCIENCE MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
FIGURE 11 AI IN LIFE SCIENCE MARKET: PORTER’S FIVE FORCES ANALYSIS
FIGURE 12 AI IN LIFE SCIENCE MARKET: VALUE CHAIN ANALYSIS (2025)
FIGURE 13 AI IN LIFE SCIENCE MARKET: ECOSYSTEM ANALYSIS
FIGURE 14 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES
FIGURE 15 TOTAL FUNDING OF PLAYERS IN AI IN LIFE SCIENCE MARKET
FIGURE 16 JURISDICTION AND TOP APPLICANT ANALYSIS FOR AI IN LIFE SCIENCE MARKET
FIGURE 17 TOP APPLICANTS & OWNERS (COMPANIES/INSTITUTIONS) FOR AI IN LIFE SCIENCE MARKET (JANUARY 2015 TO DECEMBER 2025)
FIGURE 18 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR END USERS
FIGURE 19 KEY BUYING CRITERIA FOR TOP THREE END USERS
FIGURE 20 NORTH AMERICA: AI IN LIFE SCIENCE MARKET SNAPSHOT
FIGURE 21 ASIA PACIFIC: AI IN LIFE SCIENCE MARKET SNAPSHOT
FIGURE 22 REVENUE ANALYSIS OF KEY PLAYERS IN AI IN LIFE SCIENCE MARKET, 2021–2025 (USD MILLION)
FIGURE 23 AI IN LIFE SCIENCE MARKET SHARE ANALYSIS OF KEY PLAYERS (2025)
FIGURE 24 AI IN LIFE SCIENCE MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2025
FIGURE 25 AI IN LIFE SCIENCE MARKET: COMPANY FOOTPRINT
FIGURE 26 AI IN LIFE SCIENCE MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2025
FIGURE 27 EV/EBITDA OF KEY VENDORS
FIGURE 28 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY VENDORS
FIGURE 29 AI IN LIFE SCIENCE MARKET: BRAND/SOFTWARE COMPARATIVE ANALYSIS
FIGURE 30 NVIDIA CORPORATION: COMPANY SNAPSHOT (2025)
FIGURE 31 ILLUMINA, INC.: COMPANY SNAPSHOT (2025)
FIGURE 32 TEMPUS AI, INC.: COMPANY SNAPSHOT (2025)
FIGURE 33 RECURSION: COMPANY SNAPSHOT (2024)
FIGURE 34 DASSAULT SYST?MES SE: COMPANY SNAPSHOT (2025)
FIGURE 35 SCHR?DINGER, INC.: COMPANY SNAPSHOT (2024)
FIGURE 36 MICROSOFT CORPORATION: COMPANY SNAPSHOT (2025)
FIGURE 37 SOPHIA GENETICS SA: COMPANY SNAPSHOT (2025)
FIGURE 38 RESEARCH DESIGN
FIGURE 39 RESEARCH METHODOLOGY: HYPOTHESIS BUILDING
FIGURE 40 BOTTOM-UP APPROACH
FIGURE 41 TOP-DOWN APPROACH
FIGURE 42 CAGR PROJECTIONS FROM ANALYSIS OF MARKET DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
FIGURE 43 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS
FIGURE 44 DATA TRIANGULATION
FIGURE 1 MARKET SCENARIO
FIGURE 2 GLOBAL AI IN LIFE SCIENCE MARKET, 2024–2031
FIGURE 3 MAJOR STRATEGIES ADOPTED BY KEY PLAYERS IN AI IN LIFE SCIENCE MARKET, 2023–2026
FIGURE 4 DISRUPTIONS INFLUENCING GROWTH OF AI IN LIFE SCIENCE MARKET
FIGURE 5 HIGH-GROWTH SEGMENTS IN AI IN LIFE SCIENCE MARKET, 2026–2031
FIGURE 6 ASIA PACIFIC TO REGISTER HIGHEST CAGR IN AI IN LIFE SCIENCE MARKET DURING FORECAST PERIOD
FIGURE 7 GROWING ADOPTION OF PRECISION MEDICINE AND AI IN DRUG DISCOVERY TO DRIVE MARKET
FIGURE 8 CLINICAL APPLICATIONS IN NORTH AMERICA ACCOUNTED FOR LARGEST MARKET SHARE IN 2025
FIGURE 9 JAPAN TO REGISTER HIGHEST GROWTH RATE DURING FORECAST PERIOD
FIGURE 10 AI IN LIFE SCIENCE MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
FIGURE 11 AI IN LIFE SCIENCE MARKET: PORTER’S FIVE FORCES ANALYSIS
FIGURE 12 AI IN LIFE SCIENCE MARKET: VALUE CHAIN ANALYSIS (2025)
FIGURE 13 AI IN LIFE SCIENCE MARKET: ECOSYSTEM ANALYSIS
FIGURE 14 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES
FIGURE 15 TOTAL FUNDING OF PLAYERS IN AI IN LIFE SCIENCE MARKET
FIGURE 16 JURISDICTION AND TOP APPLICANT ANALYSIS FOR AI IN LIFE SCIENCE MARKET
FIGURE 17 TOP APPLICANTS & OWNERS (COMPANIES/INSTITUTIONS) FOR AI IN LIFE SCIENCE MARKET (JANUARY 2015 TO DECEMBER 2025)
FIGURE 18 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR END USERS
FIGURE 19 KEY BUYING CRITERIA FOR TOP THREE END USERS
FIGURE 20 NORTH AMERICA: AI IN LIFE SCIENCE MARKET SNAPSHOT
FIGURE 21 ASIA PACIFIC: AI IN LIFE SCIENCE MARKET SNAPSHOT
FIGURE 22 REVENUE ANALYSIS OF KEY PLAYERS IN AI IN LIFE SCIENCE MARKET, 2021–2025 (USD MILLION)
FIGURE 23 AI IN LIFE SCIENCE MARKET SHARE ANALYSIS OF KEY PLAYERS (2025)
FIGURE 24 AI IN LIFE SCIENCE MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2025
FIGURE 25 AI IN LIFE SCIENCE MARKET: COMPANY FOOTPRINT
FIGURE 26 AI IN LIFE SCIENCE MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2025
FIGURE 27 EV/EBITDA OF KEY VENDORS
FIGURE 28 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY VENDORS
FIGURE 29 AI IN LIFE SCIENCE MARKET: BRAND/SOFTWARE COMPARATIVE ANALYSIS
FIGURE 30 NVIDIA CORPORATION: COMPANY SNAPSHOT (2025)
FIGURE 31 ILLUMINA, INC.: COMPANY SNAPSHOT (2025)
FIGURE 32 TEMPUS AI, INC.: COMPANY SNAPSHOT (2025)
FIGURE 33 RECURSION: COMPANY SNAPSHOT (2024)
FIGURE 34 DASSAULT SYST?MES SE: COMPANY SNAPSHOT (2025)
FIGURE 35 SCHR?DINGER, INC.: COMPANY SNAPSHOT (2024)
FIGURE 36 MICROSOFT CORPORATION: COMPANY SNAPSHOT (2025)
FIGURE 37 SOPHIA GENETICS SA: COMPANY SNAPSHOT (2025)
FIGURE 38 RESEARCH DESIGN
FIGURE 39 RESEARCH METHODOLOGY: HYPOTHESIS BUILDING
FIGURE 40 BOTTOM-UP APPROACH
FIGURE 41 TOP-DOWN APPROACH
FIGURE 42 CAGR PROJECTIONS FROM ANALYSIS OF MARKET DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
FIGURE 43 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS
FIGURE 44 DATA TRIANGULATION
